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2“We shall not cease from exploration
and  the end of our exploring
 will be to arrive where we started
 and know the place  for the first time.”
(Eliot, TS. Little Gidding. 1942)
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61. ABSTRACT
 Diabetes Mellitus is the most prevalent metabolic disorder characterized by 
chronic hyperglycemia due to primary defects in insulin secretion and/or insulin 
function. In the last few decades the notion of diabetes has widened, ascertain that the 
present subdivision into type 1 (T1DM) and type 2 (T2DM) diabetes is a gross 
oversimplification. Both forms of diabetes seem to result from a complex interplay 
between genes and environment. Advance technologies have revolutionized the search 
for genetic influences on complex traits. Genomewide association studies (GWAS) and 
GWAS meta-analyses have been the most efficient way to identify new T2DM genes. 
However, despite these advances, the overall effect attributed to these loci is low and 
their contribution is of little clinical usefulness compared to evaluation of classical risk 
factors such as body mass index (BMI), age and family history. Therefore, evaluation of 
glycemic control remain the primary target for diabetes treatments. However, under-
standing and utilization of single gene effects on specific traits that conglomerate into a 
complex phenotype is currently the best way to understand the genetic basis at 
functional level and could results in a possible advantage for disease prevention and 
management.
 In this light, to explore the complexity of this disorder and to give some hints in 
the pathogenesis of diabetes, we have followed a candidate gene approach by studying 
the Fructosamine 3-kinase (FN3K) gene, whose product is implicated in non-enzymatic 
glycation of proteins, in an Italian cohort of diabetic individuals. 
Glycation has long been considered irreversible. Thus, the identification of an enzyme, 
FN3K, able to reverse this process by decomposing fructosamine 3-phosphate to 
3-deoxyglucosone, inorganic phosphate and an amine, opened the perspective that 
fructosamines could be physiologically removed by proteins, suggesting a protective 
role in the development of diabetic complications and other pathologies characterized 
by high fructosamines/AGEs levels. 
 First aim of the present study was to accomplish the analysis of the FN3K gene 
in a well clinically characterized group of Italian individuals with diabetes 
(35 T1DM and 35 T2DM) belonging to ADAG study and 33 healthy subjects, by 
analyzing its promoter region. Then, the FN3K gene (promoter region and all six exons 
with corresponding intron/exon boundaries) were analyzed in additional 80 T2DM 
subjects, followed since long time in diabetic clinic.
7 The molecular screening revealed the presence of 15 different genetic variants. 
Four of them represented new mutations: the c.2 T>A (p.M1?) in the translation 
starting codon; the c.465 G>A (p.P115=) located in a consensus sequence for the 
splicing site; the c.559 C>T (p.R187*) leading to the formation of a truncated protein; 
the missense mutation c.716 A>G (p.Y239C) in exon 6. Presence of these variants 
were excluded from control group using DHPLC analysis. Other 11 variants identified 
were polymorphisms; of them 3 were new: the IVS2-27 A>G in intron 2; the c.421 
C>T and c.429delATCGGAG in the promoter region. The remaining 8 were polymor-
phisms already described: c. -232 A>T and c.-385 A>G in the promoter region; c.187 
A>C (p.R63=) in exon 2; c.900 C>G (p.S300=) and c.906 C>T (p.G302=) in exon 6; poly-
morphisms IVS+26 G>A, IVS+31 A>T and IVS4-9-11delTTG were present in non coding 
regions of the FN3K gene (intron 2, intron 2 and intron 4, respectively).
 An RNA expression study was performed on new variants (c.2 T>A; c.465 G>A; 
c.559 C>T and c.716 A>G) in order to confirm the hypothesis on pathogenicity of these 
variants found at genomic level. Furthermore, mutations c.559 C>T (p.R187*) and c.716 
A>G (p.Y239C) were analyzed in a familial context. The RNA analysis didn’t confirm 
the result predicted by in silico modelling, suggesting that these variants might exert a 
pathological function with other mechanisms or interacting with other polymorphisms 
present in non coding regions of the FN3K gene where they may produce a subtle 
difference in regulation expression. 
 A second aim was to find a correlation between genotypes and some clinical 
parameters typical of diabetes, to offer a better comprehension of glycemic control and 
its predictive role in the middle and log period. A genotype composed by the combina-
tion of 3 polymorphisms (c.-385 A>G; c.-232 A>T; c.900 C>G) mostly associated with 
a variation in FN3K enzymatic activity and with HbA1c values was considered. On the 
bases of glycated hemoglobin values of each patients, the identified genotypes were 
compared on HbA1c mean values for the different groups. The analysis didn’t find out a 
difference in HbA1c values among different groups. However, two interesting observa-
tions came out: the genotype containing the favorite alleles for the 3 polymorphisms 
(GG at c.-385 A>G; TT at c.-232 A>T; CC at c.900 C>G) seemed to be related to a low 
concentration of HbA1c; patients with different complications (macro- or micro- 
vascular) displayed different genotypes.
 The role of FN3K variants in development or progression of diabetes remain 
unclear. The lack of an association between polymorphisms identified in the FN3K gene 
and diabetes explains that probably this enzyme cannot by itself account for the entire 
deglycation story.
8It alone cannot be responsible for the susceptibility to this pathology or for the devel-
opment of its complications. 
 Moreover, recent studies provided experimental evidences for epigenetic 
mechanisms as plausible means by which environmental factors integrate their effects 
with genetic variants to mediate T2DM risk. Current research provides insights for the 
importance of nutrition in terms of health and disease prevention. Studies on the 
“epigenetic diet” have revealed that the consumption of some foods like soy, curry 
spices, red grapes, as well as blueberries has beneficial effects on the prevention of 
diseases. One way of exerting its impact is through modulation of non-coding RNA 
levels, microRNAs (miRNAs), short (≈22 nucleotides) non-coding regulatory elements 
functioning as translational repressors. miRNAs have an important role in many cellular 
processes and are proposed as promising pharmaceutical targets in various fields, such 
as cancer and metabolic diseases. Recent findings have shown that altered 
circulating miRNA profiles were linked to pathological conditions, thus raising the
possibility of their use as promising non-invasive biomarkers for the detection, 
classification and prognosis of diseases. 
 We had then the opportunity to collaborate with the University of Hull (UK), 
involved in understanding the effect of soy phytoestrogen in the management of 
diabetes. The potential health benefits of soy are widely publicized. These legumes 
contain complex carbohydrates,vegetable protein, soluble fibers, oligosaccharides,  
minerals, and phytoestrogens, particularly the isoflavones genistein and daidzein. 
 Two hundred men with T2DM and compensated hypogonadism were 
randomized and administered either 30 g of soy protein with 66 mg of isoflavones per 
day, or 30 g soy protein alone without isoflavones for 12 weeks. Given the estrogenic 
effect of phytoestrogens, the hypothesis to test was if there were any effects of soy 
with and without isoflavones on testosterone, this would be exaggerated in men with 
low testosterone levels. 
 The primary outcome of this study was the change in testosterone levels. The 
secondary outcomes were changes in glycemic control and cardiovascular risk markers 
including insulin resistance, lipid profile, highly sensitive CRP (hsCRP) and endothelial 
function. miRNA expression profile in peripheral plasma samples of 10 selected sub-
jects under active treatment with soy and isoflavons, was performed to evaluate a pos-
sible change in expression level after treatment. Fifty-seven circulating miRNAs differed 
9for about 2 fold between pre- and post-treatment, including 7 up-regulated and 50 
suppressed miRNAs. Among them miR-34a-5p, miR-144-3p and miR-19b-3p differed 
significantly between pre- and post- treatment.
 In this study, after soy supplementation changes in testosterone levels, in 
glycemic control and cardiovascular risk markers were observed. Moreover, the 
number of expressed miRNA seemed to increase after treatment. A consistent and 
truly significant effect of soy on the miRNAs plasma profile could not be demonstrated, 
since a validation study is needed to confirm these findings and proceed with further 
evaluation. However, these preliminary results are encouraging for future investiga-
tions on soy isoflavones potential and for miRNA utilization as biomarkers. 
 In conclusion, our findings provide new insights in FN3K genetics and give fur-
ther attempts on the hypothesis that phenotype might be influenced by allelic hetero-
geneity and/or mutations at multiple modifier genes. It would be interesting to analyze 
the FN3K gene in subjects belonging to the soy and testosterone study to evaluate a 
possible concomitant effect of FN3K genetic variants on the progression of the disease.
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2. INTRODUCTION
2.1 Diabetes Mellitus
 Diabetes is a group of metabolic diseases characterized by hyperglycemia resul-
ting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia 
of diabetes is associated with long-term damage, dysfunction, and failure of different 
organs, especially the eyes, kidneys, nerves, heart, and blood vessels [1].
 Diabetes mellitus has reached pandemic proportion, increasing in incidence by 
50% over the past 10 years [2]. The World Health Organization (WHO) states that 347 
million people worldwide were suffering from diabetes in 2008, which equates to 9.5% 
of the adult population. The incidence of diabetes is increasing at an alarming rate with 
estimations suggesting that this number will almost double by 2030 [2]. Diabetes 
mellitus occurs throughout the world but is more common in developed countries, due 
to rapid rise in obesity and life style changes. The greatest increase in prevalence in 
the near future, however, is expected to occur in Asia, the Middle East [3] and Africa, 
where it is likely that there will be a 50% increase in diabetes by 2030 [4].
Figure 1. Prevalence of diabetes in 2010 and future estimation for 2030. Adapted from ref. [5].
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 Traditionally diabetes has been subdivided into two broad etiopathogenic 
categories: type 1 diabetes (T1DM), also known as insulin-dependent diabetes or 
juvenile-onset diabetes, which comprises only 5-10% of those with diabetes [1][6]; and 
type 2 diabetes (T2DM), the much more prevalent category, with 90-95% of diabetic 
cases worldwide [7]. In T1DM the lack of insulin secretion due to auto-immune medi-
ated destruction of β cells causes hyperglycemia [1]. Autoimmune destruction of 
pancreas β-cells has multiple genetic predispositions and effect of environmental fac-
tors is still being understood. However, markers of immune destruction like islet cell 
auto-antibodies, auto-antibodies to insulin, GAD65, and tyrosine phosphatases IA-2 
and IA-2b and rise in circulating levels of C-peptide help in reasonably accurate diag-
nosis of T1DM and determine their clinical course [1][6]. On the other hand, in T2DM 
insulin resistance and inadequate insulin secretory response result in raised circulating 
glucose levels [1].T2DM is characterized by resistance to insulin action in tissues like 
liver, skeletal muscles and adipose tissue, which leads to other features such as dys-
lipidemia and central obesity. Although the specific etiologies are not known, autoim-
mune destruction of β-cells does not occur [8].Impaired fasting glucose (IFG) or im-
paired glucose tolerance (IGT) can provide indications of derangements in glucose 
metabolism. Patients spend a long asymptomatic period characterized by hyper-
glycemia, which is undetectable but sufficient to cause pathological changes [1].
 However, this subdivision is a gross oversimplification, and poorly describes the 
true range of such disease.T1DM and T2DM are polygenic in nature and caused by 
interactions between genetic and environmental factors. Monogenic diabetes, on the 
other hand represents rare, heterogeneous group of disorders due to genetic defects 
in single genes causing pancreatic β cell dysfunction and marked hyperglycemia [8]. 
Around 2–5% of global cases correspond to monogenic diabetes. Maturity onset 
diabetes of the young (MODY) and neonatal diabetes mellitus (NDM) represent two 
different classes of monogenic diabetes where hyperglycemia is either due to defects in 
insulin secretion, decrease in β cell mass or both [9].
 In addition of these categories, diabetes may also manifest during pregnancy 
(gestational diabetes, GDM) and under other conditions including drug or chemical 
toxicity, genetic disorders, endocrinopathies, insulin receptor disorders and in 
association with pancreatic exocrine disease (Fig. 2) [10].
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Figure 2. Etiologic classification of diabetes mellitus. Adapted from ref. [10].
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2.2 Genetics of T2DM 
 Several lines of evidence support the principle of inherited genetic susceptibility 
as an important risk factor for T2DM. There is a strong familial aggregation, with a risk 
of developing the disease of 40% for those who have an affected parent (higher if the 
mother rather than the father) and of 70% if both parents are diabetics [11]. 
Moreover, in identical monozygotic twins the concordance rate approaches 100%, 
much higher than that seen in dizygotic twins or among siblings [12]. Genetic predispo-
sition in T2DM is also supported by the observation that differences in disease 
prevalence rates exist among populations, even after migration of entire ethnic groups 
to another country, thus independent from the environmental influence [13].
 Enormous efforts have been done to identify the genetic cause of the disease. 
In the late 1990s and early 2000s family linkage approach, following the hypothesis 
that complex diseases such as T2DM may harbor major genetic mutations that are 
severe enough to cause disease under specific exposures, have been utilized to 
evaluate for co-segregation of genetic markers in multiplex families with T2DM. 
Although much effort invested, the only major success was the identification of the 
transcription factor 7-like 2 gene (TCF7L2), while most of the other putative candidates 
remained to be validated [14].
 In more recent years, advances in technology for SNP genotyping, exploitations 
of recent genetic knowledge gained from the Human Genome Project and develop-
ment of robust statistical methods have allowed genome-wide association studies 
(GWAS) to emerge as the method of choice for detecting common genetic variants 
associated with complex diseases. This methodology has helped to identify dozens of 
new associations between T2DM and genes with known or unknown functions and 
some of previous results have been confirmed [15]. To date, about 80 distinct genetic 
loci have been identified as predisposing to risks of T2DM in European populations 
through case-control studies and these are summarized in Table 1. Moreover, multiple 
other GWAS efforts have also been invested in evaluating for related quantitative traits, 
such as blood glucose and insulin levels as well as T2DM in non-European populations 
[16][17].
 Despite this dramatic success, there is a substantial gap between the discovery 
of many T2DM-associated SNPs and the understanding of how these SNPs physiologi-
cally impact T2DM pathogenesis. So far, 80% of all T2DM-associated SNPs are inter-
genic or intronic, and the geneticists have named the closest gene on the SNP chromo-
some as the T2DM-susceptibility gene without having strong clues about the molecular 
link between the gene and the variant. Furthermore, the individual effect of these SNPs
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on T2DM risk is typically modest. Each risk allele usually increases less than 15% the 
risk of developing T2DM (Odds Ratio <1.15). As a consequence, we can see that all 
common T2DM-associated SNPs have captured less than 15% of T2DM familial herita-
bility [18].
 However, in case in which was possible to ascertain the precise pathogenic 
mechanism, it has been observed that most of the genes identified are involved in 
pancreatic β-cell mass and/or function, with a consequent implication in insulin defects 
[19][20].
 The advent of GWAS era and the identification of multiple risk loci have illu-
minated the pathophysiology of T2DM and have of course confirmed the polygenic 
nature of the disease. Furthermore, the identification of these loci has also provided an 
opportunity to translate genetic information into clinical practice. For example, these 
may have potential role in disease risk prediction or in identifying subjects at risk of 
developing disease at an early-stage or in clinical management of individuals. Affected 
individuals could take advantages from the so called legacy effect, i.e., early tight diabe-
tes control resulting in a substantial micro- and cardiovascular benefit [21].
Table 1. List of identified common variants associated with T2DM in populations of European
ancestry utilizing a case-control design. Adapted from ref. [22].
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2.3 Diagnostic criteria for diabetes mellitus
 Assigning a type of diabetes to an individual often depends on the circumstan-
ces present at the time of diagnosis, with individuals not necessarily fitting clearly into 
a single category. Clinical presentation and disease progression may vary considerably 
in both type of diabetes.
 The WHO diagnostic criteria for diabetes mellitus include fasting plasma glu-
cose level ≥126 mg/dL (7.0 mmol/L) or 2-hour plasma glucose level ≥200 mg/dL (11.1 
mmol/L) after a 75-g oral glucose load [23][24]. More recently, a glycated hemoglobin 
level of ≥6.5% is recommended by WHO as the cut point for diagnosing diabetes [25].
 Moreover, there are some conditions of intermediate hyperglycemia associa-
ted with an increased risk to develop diabetes, collectively known as prediabetes [26]. 
Impaired glucose tolerance is defined as a 2-hour plasma glucose level ≥140 mg/dL (7.8 
mmol/L) and less than 200 mg/dL (11.1 mmol/L) after a 75-g oral glucose load. 
Impaired fasting glucose is defined as fasting glucose level between 110 mg/dL and 
125 mg/dL (6.1–6.9 mmol/L). Glycated hemoglobin value between 5.7% and 6.4% is 
also associated with prediabetes.
Diagnostic criteria for diabetes are summarized in Figure 3. 
Figure 3. Criteria for the diagnosis of diabetes. Adapted from ref. [1]
16
2.4 Diabetic complications: the “non-enzymatic glycation hypothesis”
 Diabetes is a common condition with multiple complications. Symptoms of 
marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with 
polyphagia, and blurred vision. Impairment of growth and susceptibility to certain 
infections may also accompany chronic hyperglycemia [27][28]. In human diabetes, 
hyperglycemia leads to long-term complications such as retinopathy with potential loss 
of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot 
ulcers, amputations, Charcot joints; and autonomic neuropathy causing gastrointesti-
nal, genitourinary, and cardiovascular symptoms and sexual dysfunction. Patients with 
diabetes have an increased incidence of atherosclerotic cardiovascular, peripheral 
arterial and cerebrovascular disease. Moreover, hypertension and abnormalities of 
lipoprotein metabolism are often found in people with diabetes [27][28]. 
 To date, there has been much work done to elaborate on the etiology, preven-
tion and treatment of diabetes related complications. The DCCT [29] and UKPDS [30] 
studies have emphasized the role of tight glucose control as being important in redu-
cing diabetes microvascular complications in T1DM (DCCT) and T2DM (UKPDS). On the 
other hand, the relation between tight glucose control and macrovascular complica-
tions is not yet clear [31].
 Many hypotheses have been proposed to link the elevated concentration of 
glucose and the development of related complications [32][33][34]. One of the leading 
proposals is the ‘‘non-enzymatic glycation hypothesis’’ which postulates that the 
deleterious effects of chronic hyperglycemia are a result of excessive non-enzymatic 
modification of proteins and some phospholipids by glucose and its by-products [34]
[35].
 Glycation, also known as Maillard reaction, is a common and spontaneous reac-
tion, occurring in vivo [36]. Protein glycation refers to the binding of glucose or other 
reducing sugars to proteins. Particularly, glycation with aldoses takes place with the 
ε-amino group of lysine residues or with the N-terminus of the protein, resulting in the 
formation of a Schiff base product. This thermodynamically-unstable compound 
rearranges to form ketoamine derivatives, the Amadori products, that can undergo a 
series of further rearrangements (dehydration, cyclization, fragmentation and 
oxidation) to form a wide and heterogeneous group of complex compounds called 
advanced glycation end products (AGEs) (Fig. 4) [37]. Both fructosamines and AGEs can 
impair structural and biological properties of proteins in living organisms, with a 
complex mechanism at least in part independent of hyperglycemia [38][39].
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Figure 4. Schematic representation of Maillard reaction and some AGEs formation. 
CEL= carboxyethyllysine; MOLD= methylglyoxal lysine dimer; DOLD= 3-deoxyglucosone lysine 
dimer; CML= carboxymethyllysine; GOLD= glyoxal lysine dimer. Adapted from ref. [40].
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2.4.1 Advanced glycation end products and diabetes
 AGE formation and accumulation increasingly occurs under diabetic condi-
tions, and even if glycemic control is restored, AGEs can remain in tissues of diabetic 
subjects for a long time[41]. In people with diabetes, AGE formation is accelerated due 
to increased concentration of circulating glucose, AGE precursors and oxidative stress. 
In serum and tissues of patients with T1DM as well as T2DM, increased levels of AGEs 
have been found. Furthermore, accumulation of AGEs in diabetic tissue was shown to 
correlate with diabetic complications [42].
 The damaging potential of AGEs results from direct alterations on protein 
structures and functions due to AGEs per se or the cross-linking effect of some AGEs 
[43]. AGEs are often found in the extracellular matrix and thus modified matrix proteins 
impair matrix-matrix as well as matrix cell interactions. This may cause cell death, cell 
differentiation or reduced cell adhesion and migration [44]. Intracellular proteins are 
also targets of modifications and AGE formation was shown to impair their functions 
[45]. Besides direct changes in protein structures and functions, AGE-mediated damage 
occurs via binding of AGEs to the receptor of advanced glycation end products (RAGE) 
[46]. RAGE belongs to the immunoglobulin superfamily and additionally interacts with 
a wide range of AGEs which is why RAGE is also classified as a multi-ligand receptor. In 
recent years the interaction of AGEs with RAGE was studied in vitro pointed out that 
ligand binding to RAGE activates NAPDH oxidases and thus increases intracellular ROS 
formation [47][48]. Increased ROS in turn leads to AGE formation, which triggers all 
described damaging mechanisms mediated by AGEs, but also activates the transcrip-
tion factor nuclear factor kappa B (NFκB) [49]. Activation of NFκB increases the 
expression of pro-inflammatory cytokines such as interleukin 6 [50] and monocyte 
chemoattractant peptide 1 (MCP-1) [51] as well as RAGE itself [52] thus intensifying the 
inflammatory response.
 Glycation of proteins is a major cause of spontaneous damage to the proteome. 
In recent years, the traditional view of glycation has been confirmed and new insights 
established. AGEs are particularly insidious since they play an important role in the 
pathogenesis of diabetic complications that are the principal cause of morbidity and 
mortality of diabetic patients. It is nevertheless critical to identify logical and directed 
targets for prevention and therapy. In future research it will be important to identify 
proteins and hotspot sites within them susceptible to glycation. Probably the most 
potent strategy will be to develop inducers of enzymatic defense against glycation [53]
[54] such as FN3K.
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2.5 Fructosamine 3-kinase
 Repair is of outstanding importance for life and three different types of 
enzymes are known to metabolize ketoamines: oxidases, isomerases and kinases [55]
[56]. However, only the latter is used to deglycate proteins under physiological condi-
tions. 
 The discovery of Fructosamine 3-kinase (FN3K), a protein distantly related to 
aminoglycoside kinases and, even more distantly, to protein kinases [57], able to repair 
fructosamines, opened new conceptual avenues on Maillard reaction. 
 The starting point for the discovery of FN3K, was the identification of fructose 
3-phosphate in human and animal tissues [58]. This enzyme exhibited a very low affini-
ty for its substrate (Km≥ 30 mM) and a low metabolic capacity, suggesting that it could 
act on some substrates different from fructose, even if on compounds with a closely 
related structure [58]. Two independent groups led to the conclusion that “fructose 
3-kinase” phosphorylates fructosamines with a Km in the micromolar range, i.e. 4–5 
orders of magnitude lower than the Km for fructose (≈50–100 mM). 
 FN3K appears to represent a part of a cellular defense and/or repair system to 
control non enzymatic glycation of proteins. Indeed, the enzyme phosphorylates not 
only fructosamines, but also their C3-epimers psicosamines, as well as ribulosamines 
and erythrulosamines, even if psicosamines are much poorer substrates than the other 
ketoamines [59]. In details, FN3K would be able to break down the second interme-
diate of the non-enzymatic glycation cascade by phosphorylating fructoselysine to a 
fructoselysine-3-phosphate (FL3P). The latter compound spontaneously decomposes 
by β-elimination, regenerating an unmodified lysine along with inorganic phosphate 
and 3-deoxyglucosone, then readily detoxified to inert products such as 
3-deoxyfructose or 2-deoxy-3-ketogluconic acid [57][59] (Fig. 5). 
Figure 5. Glycation process and
FN3K role in phosphory-
lation with spontaneous 
deglycation of the Ama-
dori product. Adapted 
from ref. [60]
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 The enzyme was purified from human erythrocytes [59] and its cDNA was 
cloned [57]. 
Human FN3K is a monomeric protein of 309 amino acids encoded by a gene 
(NC_000017.10) located on chromosome 17q25.3. FN3K gene may have arisen by an 
event of duplication of an ancestral gene, FN3K-Related Protein (FN3K-RP). The gene 
encoding FN3K-RP is located 8 kb upstream of the FN3K gene, and share a 65% 
sequence homology with FN3K and an identical genome organization and same 
orientation on the chromosome (Fig. 6) [61][62].
Figure 6. FN3K genomic organization. Adapted from ref. [62].
 Both FN3K and FN3K-RP genes have 6 exons with the initial ATG in exon 1 and 
a STOP codon in exon 6. The intron-exon junctions are in homologous position and 
both genes are characterized by a large fourth intron. Analysis of the core promoters 
of these genes showed two similar sequences without TATA or CCAAT boxes and high 
in GC. Such promoter sequences are consistent with those of housekeeping genes, 
and suggest they are likely to be expressed in a large variety of tissues [63]. mRNA for 
both genes was detected, with especially high levels of FN3K, in tissues susceptible to 
diabetic complications such as the kidney, heart and peripheral and central nervous 
systems [63]. Furthermore, starvation and diabetes do not change the level of 
expression of FN3K in different tissues, and no regulation of FN3K expression was 
observed in human fibroblasts treated with condition mimicking the diabetic state, 
strengthening the idea of an housekeeping gene (Fig. 7) [63]. 
Figure 7. Relative levels of
FN3K and FN3K-RP 
mRNA in human tissues 
(normalized to β-actin 
message) as assessed 
by quantitative RT-PCR. 
Adapted from ref. [63].
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Both FN3K and FN3K-RP phosphorylate psicosamines and ribulosamines, but only the 
former act on fructosamines [61].
 FN3K involvement in deglycation was first provided by finding that its competi-
tive inhibitor, deoxymorpholino-fructose (DMF), increases about 2-fold the rate of 
accumulation of glycated hemoglobin when erythrocytes are incubated in presence of 
200 mM glucose [60]. Definitive evidence for FN3K being responsible for deglycation 
was provided in animal models: FN3K-/- mice showed a level of hemoglobin-bound 
fructosamines of about 2.5-fold higher than those observed in FN3K+/+ or FN3K+/- 
mice [64]. However, FN3K has been recently demonstrated to be able to reduce the 
glycation of intracellular islet proteins, but does not affect pancreatic β-cell survival 
and function, even if these are incubated for several weeks in presence of high glucose 
concentration [65]. 
 The demonstration that FN3K phosphorylates glycated hemoglobin in intact 
cells causing its partial deglycation was followed by experiments aimed to identify the 
fructosamines residues removed from hemoglobin in intact erythrocytes, as a result 
of FN3K action. In vitro studies indicated that several fructosamines bound to lysines 
are excellent substrates, whereas others are only poorly phosphorylated [66]. Thus, 
the fructosamines bound to Lys139α, located near the C-terminus of α subunits, and 
Lys16α, located on a loop of α subunits, are good substrates. On the contrary, fructose 
bound to Lys61α, whose side chain is partially bound to a heme, is only very slowly 
phosphorylated. Moreover, the N-terminal glycated valine is a poor substrate, consi-
stent with free fructosevaline being a much poorer substrate than free fructoselysine 
[67].
 The physiological importance of deglycation is unknown at present. Deglycation 
might prevent the further conversion of fructosamines into advanced glycation pro-
ducts. FN3K would be expected to act on glycated residues that are most accessible 
and that would therefore be more likely to cause covalent cross-linking of proteins. 
Another potential role is to prevent the loss of residues that play a critical role in 
enzyme catalysis or protein function [66]. However, enzymes sometimes undergo 
conformational changes during catalysis. A glycated lysine might therefore become 
accessible in an open conformation of an enzyme. Moreover, FN3K could prevent the 
loss of residues playing a role in protein/protein interactions, that are expected to be 
rather freely accessible to FN3K [66].
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2.5.1 FN3K variability in humans
 The pathogenesis of diabetes is incredibly complicated as depicted by the 
number of pathways implicated. Diligent control of glycemia and blood pressure stabi-
lize the level of morbidity and mortality associated with diabetes [68]. However, good 
glycemic control alone has been shown to be insufficient to prevent death from cardio-
vascular event [69] and may increase risk of adverse events [70]. 
 The human erythrocyte FN3K activity, which is stable with time in a single indi-
vidual, is highly variable from person to person. This variability is apparently not due to 
differences in blood glucose levels or insulinemia, in addition FN3K activity is not dif- 
ferent in erythrocytes from T1DM and normoglycemic subjects [71]. It was reported 
that the real role of FN3K enzyme in the development of diabetic complications could 
be demonstrated by comparing the development of complications in patients with low 
and high FN3K activities on a large cohort of diabetic patients categorized according to 
known factors predisposing such complication [71]. Different approaches for the 
measurement of FN3K activity were described. First of all, FN3K has to be partially 
purified from the erythrocyte lysate in order to determine its activity in erythrocytes 
[59]. Phosphorylated products are then detected using 31P nuclear magnetic 
resonance (NMR) spectroscopy. A second strategy is based on the use of the substrate 
fructose-1,4-(3-aminoethyl)-piperazine and the radiolabeled cosubstrate [γ-33P]-ATP. 
Quantification of the 33P-labelled phosphorylated product is performed by utilising a 
scintillation technique after removal of the excess of cosubstrate. In a third approach 
the radiolabelled substrate 14C-deoxymorpholinofructose (14C-DMF) is used. For the 
scintillation analysis the phosphorylated product 14C-DMF is isolated using an anion-
exchange column. In this case, activity studies are performed using intact erythrocytes 
or partially purified FN3K [72]. However, these methods are time consuming and 
inappropriate for routine analysis on large series of subjects, for the use of radioactive 
substrates and/or NMR equipment. Moreover these methods seem to be deficient in 
terms of analytical performance for the current clinical use.
 A more realistic approach in understanding the FN3K possible role in diabetic 
complications would be to analyze the presence of different SNPs in the FN3K gene, 
previously linked to FN3K enzymatic activity [71].
 First, Delpierre and collaborators reported an association between FN3K en-
zymatic activity in red cells and some polymorphisms in the FN3K gene, in a Belgian 
cohort of 31 T1DM subjects and 26 controls [71]. They found that two SNPs, besides 
other gene variants, the CC of the c.900C>G (rs1056534) in exon 6 and the GG of the 
c.-385A>G (rs3859206) in the promoter region, were associated with reduced 
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enzymatic activity measured in erythrocytes. However, they failed to detect a correla-
tion between FN3K SNPs and HbA1c levels [71]. Then, the group of Mohás analyzed 
a large cohort of T2DM subjects (859 T2DM and 265 controls) for the presence of the 
polymorphism c.900C>G (rs1056534) of the FN3K gene [73]. They found that the C 
allele of rs1056534 was coupled with lower HbA1c concentration and with a later onset 
of type 2 diabetes. However, no association between this variant and diabetic compli-
cations, such as nephropathy, neuropathy or retinopathy, was found in their investiga-
tion. In 2014, a group of 314 T2DM subjects was screened for 19 SNPs in six candidate 
genes encoding for enzymes of metabolic pathways, in order to verify if the genetic 
variability in such genes could influence the progression of diabetic nephropathy. An 
association of the polymorphism in exon 6 (rs1056534) of the FN3K gene with the 
progression of diabetic nephropathy and cardiovascular morbidity and mortality was 
indeed reported [74]. Recently, Škrha and co-workers, in a cohort of 129 T1DM, 340 
T2DM and 126 controls, evaluated the association of FN3K and GLO1 polymorphisms 
with parameters of endothelial dysfunction and soluble receptor for AGEs (sRAGE) [75]. 
In 126 subjects (50 T1DM, 52 T2DM and 24 healthy individuals), a significant associa-
tion of FN3K rs1056534 and rs3848403 SNPs with sRAGE concentration in patients with 
diabetes was proven. Our research group has also analyzed a Caucasian cohort of 70 
diabetic patients, 35 T1DM and 35 T2DM and 33 controls, for the coding part of the 
FN3K gene, identifying two new mutations and additional variants within the gene. No 
significant association was found between certain SNPs and diabetic conditions. How-
ever, we noted too that the genotype containing c.900 CC alleles (rs1056534) seemed 
to be related with low concentration of HbA1c [76].
 The interpretation of FN3K polymorphisms and their role in influencing the 
enzymatic activity is hard to evaluate. None of the identified polymorphisms resulted in 
a modification of the sequence of the encoded protein, indicating that the differences 
in activity are not due to the production of a hypo- or hyper-active protein. 
Furthermore, none of the polymorphisms were present in a consensus sequence for a 
splicing site or for the binding of a transcription factor, suggesting that they are not by 
themselves responsible for the variations in FN3K activity. A likely explanation is that 
they are in linkage disequilibrium with polymorphisms in regulatory sequences 
(enhancer element) [71]. 
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2.6 MicroRNA
 The most well-studied sequences in the human genome are those of protein-
coding genes. However, the coding exons of these genes account for only 1.5% of 
the genome, a proportion that increases to 2% if untranslated regions (UTRs) are 
considered [77]. In recent years, it has become increasingly apparent that the non-
protein-coding portion of the genome is of crucial functional importance for normal 
development and physiology and for disease [78]. The functional relevance of the 
non-protein-coding genome is particularly evident for a class of small non-coding RNAs 
(ncRNAs) called microRNAs (miRNAs) [79][80]. 
 They were first described in 1993, in C.elegans as RNA molecules that regulate 
the developmental timing in the organism [81]; however, after less than two decades, 
thousands of miRNAs have been identified in plants and animals, including approxi-
mately 2,000 miRNAs in humans (miRBase) [82]. 
 miRNAs are short (19–24 nucleotides in length) non-coding RNAs that regulate 
messenger RNA (mRNA) or protein levels either by promoting mRNA degradation or by 
attenuating protein translation. Based on computational prediction, it has been 
estimated that more than 60% of mammalian mRNAs are targeted by at least one 
miRNA [83]. 
Biogenesis of miRNAs starts in the nucleus, where long primary molecules (pri-miRNAs) 
are transcribed by RNA polymerase II [84], or in some cases by RNA polymerase III 
[85]. The primary transcript is processed by the nuclear RNase III-type enzyme Drosha 
into a shorter miRNAs precursors (pre-miRNAs) [86]. After the initial processing in the 
nucleus, pre-miRNAs are then exported to the cytoplasm by the complex of Exportin-5 
[87]. A Dicer enzyme cleaves the molecules, which then form RNA-induced silencing 
complex (RISC). By attaching themselves to complementary sequences of the target 
RNA,the RISC complexes improve their stability and help in mRNA translation. miRNA 
inhibits protein synthesis by interacting with partially complementary regions near the 
3’-end, which do not undergo translation. Upon binding, the miRNA initiates a pathway 
that either degrades the transcripts or suppresses their translation [88][89] (Fig. 8).
 Mature miRNA regulated gene expression contributes to essential cellular pro-
cesses such as differentiation, apoptosis and proliferation [91]. Quantitative detection 
of cellular miRNAs has been suggested to define disease status, as abnormal presence 
of certain miRNAs correlates with the pathogenesis of diseases such as cancer and 
diabetes [92]. 
 Importantly, miRNAs can also be detected outside of cells [93][94]. This fraction 
of miRNAs is regarded a cell-free circulating molecules residing in various extracellular 
25
vesicles such as microparticles, exosomes [95] and apoptotic bodies [96]; or conjugated 
with RNA binding proteins [97] or lipoprotein complexes [98] (Fig 8).
Figure 8. Overview of miRNAs biogenesis. miRNA biogenesis begins with transcription of 
pri-miRNA transcripts by RNA polymerase II or III (1). In the nucleus, pri-miRNAs are processed 
by Drosha to produce pre-miRNA hairpins (2), which are then exported into the cytosol (3). 
Here, pre-miRNA hairpins are processed into 19–24 nucleotide mature miRNA duplexes by 
Dicer (4). One strand of the mature miRNA duplex is incorporated into the RISC complex 
where it can regulate expression of target mRNAs (5). The other strand may either be 
degraded, or possibly prepared for export from the cell (6). Some miRNAs have been found 
packaged in exosomes derived from multivesicular bodies (7). Others may be exported in the 
presence of RNA-binding proteins (8). Still others might be exported microvesicles shed during 
membrane blebbing (9). Once in the extracellular space, these miRNAs could be taken up by 
other cells, degraded by RNases, or excreted (10). Adapted from ref. [90].
 However, the function of these circulating extracellular miRNAs remains poorly 
understood. One of the most intriguing ideas is that extracellular miRNAs are used as 
mediators of cell–cell communication [94][99][100].
A growing list of reports indicates that these circulating miRNAs can be detected and 
quantitatively analyzed in biofluids, including serum, plasma, urine, and saliva [90].
 Although the target genes and biological functions of individual miRNAs re-
main largely unknown, there is a growing body of evidence indicates that miRNAs have 
diverse functions in both normal and pathological states [101][90]. Therefore, investi-
gation of miRNA regulation and function may add new diagnostic and therapeutic tools 
for various diseases. There is great expectation for miRNAs as novel biomarkers with 
diagnostic, prognostic and predictive value. However, we are still at a primordial phase 
of these investigations and so far no miRNA has been validated to be superior to the 
traditional biomarkers in use.
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2.6.1 Soy and isoflavons
 Diet plays an important role in daily life. People nowadays consider nutrition 
not just as nourishment, but are more conscious about food and define their lifestyle 
by what they eat. Also, there is growing public interest in achieving and sustaining 
good health through healthy eating. It is well recognize that changes in lifestyle and 
the intake of diets low in fat and high in complex carbohydrates from grains, fruits, and 
vegetables is associated with a lower risk of chronic disease [102]. 
 The potential health benefits of soy are widely publicized. Research over the 
past two decades has led to renewed interest in health and nutritional aspects of soy-
foods that focuses on much more than their protein and fat content. There is particular 
interest in understanding the possible protective role of soy against coronary heart 
disease [103][104], certain forms of cancer, such as breast and prostate cancer [105]
[106], osteoporosis [107], and alleviation of menopausal hot flushes [108].
 Isoflavones are diphenolic compounds present in plants like soybeans, red 
clover, and kudzu root. Soy is the most common dietary source for isoflavones. The 
predominant isoflavones in soy are genistein, daidzein, and, in lower concentration, 
glycitein. Soy isoflavones have structural similarities to endogenous 17β-estradiol, 
which explains their extrogenic activity and identifies them as phytoestrogens (Fig. 9).
Figure 9. Molecular structures of 17β-estradiol and isoflavones genistein, daidzein and glycitein.
MW= Molecular weight.
 Because of this structural and functional similarity to estradiol, soy isoflavones 
are able to selectively bind to estrogen receptors (ER) with distinct affinities, modulat-
ing the recruitment of co-repressors and co-activators and thus affecting ER-signaling 
[109]. Independent of ER binding, isoflavones and especially genistein, hold the po-
tential to exert physiological effects since they affect signal transduction pathways by 
inhibiting the activity of many enzymes (e.g., tyrosine protein kinase, mitogen activated 
kinase, and DNA topoisomerase) and regulating cellular factors that control the growth 
and differentiation of cells [110][111].
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2.6.2 Plasma profile of microRNAs after soy supplementation in patients 
with T2DM and subclinical hypogonadism–a randomized double-blind 
parallel study: Rationale of the study
 Isoflavones exposure has been shown to lowers circulating testosterone levels 
and sperm concentration in rodents [112][113]. In humans only one report on inverse 
association between soy food intake and sperm concentration has been reported so far 
[114], and a case report describing a 60 years old man who developed gynecomastia 
allegedly in response to the consumption of soymilk [115]. However, in contrast to the 
effects in rodents, a recently published meta-analysis of the clinical research found that 
there were no effects of soyfoods or isoflavone supplements on total or free testoste-
rone or dihydrotestosterone levels [116]. Similarly, the clinical evidence shows that soy 
does not raise estrogen levels [117]. Finally, testosterone deficiency is common in men 
with type 2 diabetes [118], and lower testosterone levels seems to be due to a combi-
nation of factors, including obesity and insulin resistance [119][120].
 Given the estrogenic effect of phytoestrogens, a randomized double-blind, 
parallel study was undertaken in men with T2DM and compensated hypogonadism. 
The hypothesis to test in this study was if there were any effects of soy with and with-
out isoflavones on testosterone levels, this would be exaggerated in men with low 
testosterone levels. The primary outcome of this study was the change in testosterone 
levels. The secondary outcomes were changes in glycemic control and cardiovascular 
risk markers including insulin resistance, lipid profile, highly sensitive CRP (hsCRP) and 
endothelial function.
 Then, miRNA expression profile was assessed in peripheral plasma samples of 
10 subjects in order to evaluate a possible change in expression level after treatment 
with soy and isoflavones. 
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3. AIM OF THE STUDY
 Genetic studies have greatly contributed to our understanding of diabetes 
mechanisms by identifying new genes and pathways, previously not linked to diabetes 
based on existing hypothetical models. However, the impact of these findings in the 
clinic with respect to identification of predictive and prognostic markers as well as new 
therapeutic targets, is still low and unsatisfying. 
 Aim of the present study was investigating on genetic variation contributing to 
glycaemic trait variability, representing a fascinating line of research because it is 
centered to the pathophysiological processes leading to diabetes through the relation-
ships to other metabolic traits. In particular, we focused our study on the molecular 
characterization of the FN3K gene, whose product is implicated in non-enzymatic 
glycation reaction, in a population of Italian individuals with diabetes. First, the analysis 
of the FN3K gene in a well clinically characterized cohort of 35 T1DM and 35 T2DMand 
33 healthy subjects, was completed by analyzing its promoter region. Then, the FN3K 
gene (promoter region and all six exons with corresponding intron/exon boundaries) 
were analyzed in additional 80 T2DM subjects, followed since long time. The main 
purposes was to identify and investigate on genetic variants within the FN3K gene and 
correlate genotypes with some clinical parameters typically associated with diabetes in 
order to offer a better comprehension of the glycemic control and of its predictive role 
in the middle and long period of the disease. 
 A second and innovative aim of this work refers to new evidences for an
 epigenetic role in influencing the development of diabetes. Particularly, environmen-
tal exposure to nutrients may change gene expression and alter disease susceptibility 
through epigenetic modifications. For this purposes miRNA plasma profile of 10 
subjects with T2DM and compensated hypogonadism administrated with soy and 
isoflavons was investigated to evaluate a possible effect of soy in influencing miRNA 
expression level.
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4. MATERIALS AND
METHODS
4.1 FN3K ANALISYS
4.1.1 Patients
Diabetic subjects analyzed for the FN3K gene were totally 150. All the individuals were 
recruited at the outpatient Diabetic Center of the Department of Medical and 
Surgical Sciences at the University of Padua. Patients were recruited in different period: 
the first, cohort 1 was made up of 70 patients, 35 T1DM and 35 T2DM; while the 
second, cohort 2, consisted of 80 T2DM subjects.
Diabetic subjects belonging from a subgroup of patients enrolled in the ADAG (A1c-
Derived Average Glucose) study [121]. The presence of T1DM and T2DM was assessed 
according to WHO criteria [24]. The diabetic patients had to have stable glycemic 
control, as shown by two HbA1c values in the 6 months prior to enrolment, with a 
variation of no more than 1%. Furthermore, they had to be able to perform self-
monitoring of blood glucose and continuous glucose monitoring. 
Patients affected by any condition that could cause changes in glycemic concentra-
tions, as disease requiring steroid therapy or plans for pregnancy during the study, as 
well as patients affected by any condition that could influence HbA1c concentrations 
(anemia, high erythrocyte turnover, blood loss, transfusions, hemoglobinopathies, liver 
and kidney disease, infections) were excluded from the study. All diabetic patients were 
between 18 and 70 years of age.
The control cohort consisted of 33 healthy blood donors also recruited from Padua 
Hospital. Control subjects had no history of diabetes, fasting glucose values ≤100 mg/
dL and HbA1c levels comprises between 4 and 6%. Blood samples were collected in 
EDTA tubes and stored at –80°C until use.
Written informed consent was obtained from all participants, also with regards to 
genetic testing. The study was approved by the local Ethic Committee and was 
conducted in accordance with the Declaration of Helsinki [122].
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4.1.2 DNA extraction 
DNA was extracted from whole blood of subjects using the QIAamp® DNABlood Mini 
Kit (QIAGEN); the procedure comprised 4 steps and was automated on the QIAcube 
(QIAGEN) (Fig. 10), an instrument that uses advanced technology to process QIAGEN 
spin columns, enabling seamless integration of automated, low-throughput sample 
preparation. Up to 12 samples could be processed per run.
Figure 10. QIAcube instrument. The outside on the left and the inside on the right.
The principle of the QIAcube extractor is based on the lysis and elimination of red 
blood cells and on the subsequent extraction of genomic DNA from leukocytes through 
cells lysis by using an anionic detergent. Contaminating RNA is removed by enzymatic 
treatment, while other contaminants, such as proteins, are eliminated by separation on 
pre-packed columns.
Sample preparation using QIAcube followed the same 4 steps as the manual spin 
procedure (Fig. 11). Each whole blood sample was thawed and 200 μL were used 
for DNA extraction in order to obtain about 3-12 μg of DNA. Briefly, optimized buf-
fers lysed samples, stabilized nucleic acids and enhanced selective DNA adsorption 
to the QIAamp membrane. Alcohol was added and lysates were loaded onto the spin 
columns. DNA was adsorbed onto the silica membrane during a brief centrifugation. 
Salt and pH conditions in the lysate ensured that proteins and other contaminants, 
which could inhibit PCR and downstream enzymatic reactions, were not retained on 
the membrane. DNA bound to the membrane was washed in two centrifugation steps 
by using two different wash buffers; wash conditions ensured the complete removal 
of any residual contaminants without affecting DNA binding. Purified DNA was then 
eluted from the spin column in a concentrated form in a low salt buffer (100 μL final 
volume).
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The concentration of DNA extracted was checked by spectrophotometry; DNA purity 
was assessed through λ260/λ280 ratio (expected ratio ca. 1.75).
DNA was stored at -20 °C until its use.
 Figure 11. Schematic representation of the spin procedure for
DNA extraction by using the QIAamp® DNA Blood Mini Kit
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4.1.3 DNA Amplification
Extracted DNA was amplified by means of Polymerase Chain Reaction (PCR). Primers 
were designed to amplify the promoter region and the 6 exons and the corresponding 
intron/exon boundaries of FN3K gene [71], in order to exclude pseudogene amplifica-
tion located on chromosome 22 [61].
Specificprotocols were developed in our laboratory in order to amplify the largest num-
ber of exons with the same protocol. Because of its length, exon 6 was divided into two 
parts and amplified with two different PCR reactions.
Table 2 shows the length of PCR products and some characteristics of the primers 
(sequence, melting temperature) used in each PCR amplification.
Table 2. PCR products lengths, primers sequences and melting temperature (Tm).
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Each PCR reaction was performed in a total volume of 25μL (PCR mixture).
PCR mix for amplification of the promoter region:
• 16μL H2O
• 2.5 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 0.6 μL 25 mM MgCl2
• 2 μL 2.5 mM dNTPs
• 1 μL 12 mM primer forward
• 1 μL 12 mM primer reverse
• 0.4 μL FastStartTaq® DNA Polymerase
• 1,5 μL genomic DNA
PCR mix for amplification of exon 1:
• 14.4 μL H2O
• 2.5 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 0.8 μL 25 mM MgCl2
• 2 μL 2.5 mMdNTPs
• 2 μL 10 mM primer forward
• 2 μL 10 mM primer reverse
• 0.3 μL AmpliTaq® Gold DNA Polymerase
• 1 μL genomic DNA
PCR mix for amplification of exons 2, 3, 4, 5, 6-(5’):
• 13.7 μL H2O
• 2.5 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 1.5 μL 25 mM MgCl2
• 2 μL 2.5 mMdNTPs
• 2 μL 10 mM primer forward
• 2 μL 10 mM primer reverse
• 0.3 μL AmpliTaq® Gold DNA Polymerase
• 1 μL genomic DNA 
PCR mix for amplification of exon 6-(3’):
• 14.3 μL H2O
• 2.5 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 0.9 μL 25 mM MgCl2
• 2 μL 2.5 mMdNTPs
• 2 μL 10 mM primer forward
• 2 μL 10 mM primer reverse
• 0.3 μL AmpliTaq® Gold DNA Polymerase
• 1 μL genomic DNA
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Two different programs on a thermal cycler (GeneAmp® PCR System 9700, Applied 
Biosystems) were used for PCR amplifications.
For the promoter region:
• 1 cycle at 96 °C for 10 minutes, to ensure the complete denaturation of template 
DNA and the activation of the polymerase;
• 30 cycles, each one composed of: 95 °C for 40 seconds (DNA denaturation),62.2°C for 
60 seconds (primers annealing), 72 °C for 60 seconds (DNA extension);
• 1 cycle at 72 °C for 10 minutes to fill-in the protruding ends of reaction products.
For all exons:
• 1 cycle at 96 °C for 10 minutes, to ensure the complete denaturation of template 
DNA and the activation of the polymerase;
• 35 cycles, each one composed of: 95 °C for 30 seconds (DNA denaturation), 56°C for 
60 seconds (primers annealing), 72 °C for 60 seconds (DNA extension);
• 1 cycle at 72 °C for 5 minutes to fill-in the protruding ends of reaction products. 
For each amplification protocol, a negative control was used: it consisted of a PCR 
mixture aliquot with no DNA added. Negative control had to give no PCR products and 
was indicative of the presence or absence of contamination in the reaction. Once the 
amplification was completed, agarose gels were prepared in order to test the quality of 
the PCR products.
Agarose gel could be prepared at different percentages to allow the separation of PCR 
products on the basis of their lengths, expressed as base pairs. For the confirmation of 
our PCR products, a 2% agarose gel was sufficient. In order to prepare a 100 mL 
solution, 2 g of agarose were weighed and added to 100 mL of TAE buffer (10 mM Tris/
HCl, pH 8.0, 1 mM EDTA); the solution was then brought to the boil until it was 
limpid. After cooling, 8μL of GelRed™ 10000X (Biotium) were added; this red 
fluorescent nucleic acid dye can be excited with a common300 nm UV transilluminator. 
Three microliters of amplified DNA were mixed with 2 μL of the gel-loading buffer 
(GelPilot DNA Loading Dye 5X, QIAGEN), previously diluted 1:2, and the samples were 
loaded into the gel wells. For sizing the PCR products (217 to 314 bp), a DNAladder 
(GeneRuler™ 100 bp DNA Ladder, Genenco) was always used; it contained the follow-
ing 11 discrete fragments: 1031, 900, 800, 700, 600, 500, 400, 300, 200, 100and 80 bp.
The amplification protocol for FN3Kgene was performed using Biomek NXP (Beckman 
Coulter). BiomekNXP puts every aspect of liquid handling, including pipetting, dilution, 
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Figure 12. Biomek NXP
 (Beckman Coulter).
Biomek NXP offers proven pipetting performance for low-volume reaction setup and 
assay miniaturization, as well as accurate and repeatable results extending into the 
submicroliter range. Since many functions are combined into a single step, setup is fast 
and effortless.
Automation of reaction setup can also eliminate both human error and contamination 
associated with manual processing, while assuring high quality results. The reliability of 
this instrument, repeatable pipetting, tube to plate capability and an efficient automa-
tion combine to provide an ideal automation solution for the amplification protocol.
Moreover its low-volume capability helps miniaturize reaction setups and save on 
costly reagents.
Biomek NXP combined with robust Biomek Software is used to manage and program 
the instrument (Fig. 13). This software provides the ability to customize the interface 
setting for every PCR step, as type of tip to use, source and destination of reagents and 
it is able to configure methods with drag-and-drop ease. The users have only to pre-
pare the worktop with tips, reagents, tubes, primers, DNA and plate of destination in 
the correct position.
 Figure 13. Software interface
of Biomek NXP.
dispensing and integration, into a single, automated system that is as powerful and flexible as it 
is efficient and economical (Fig. 12).
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4.1.4 Purification of PCR products
Amplicons have to be purified to eliminate excess oligos, nucleotides, salts, enzymes 
and other contaminants that may inhibit subsequent reactions. The purification was 
performed using AMPure® PCR Purification Kit (Agencourt® Bioscience Corporation) 
(Fig. 14) and automating the process through Biomek 3000 (Beckman Coulter).
The Agencourt AMPure method utilizes Solid Phase Reversible Immobilization (SPRI) 
magnetic bead-based technology, which requires no centrifugation or filtration. The 
Agencourt AMPure purification process binds PCR amplicons to para-magnetic 
particles and draws them out of solution, allowing contaminants such as primers, 
primer dimers, salts, and dNTPs to be easily rinsed away providing purified PCR product 
ideal for downstream genomics applications. The para-magnetic particles a 
reconstituted for 40% of magnetite and have uniform size (1 μm); their negative charge 
binds PCR products 100 bp and larger. Placed in a magnetic field, the amplicons remain 
bound to the magnetic beads in the plate wells, while the washes are performed and 
the contaminants removed. At the end the purified DNA is eluted with dd H2O and 
transferred to another plate.
 Figure 14. Schematic 
representation of PCR 
purification.
The AMPure procedure is performed in 8 steps:
1. MixAMPure reagent with the PCR reaction mixture. Add 1.8 ΜlAMPure per1.0 μL of 
PCR product;
2. Bind PCR products to para-magnetic beads and incubate for 3-5 minutes;
3. Move the plate on the magnetic support, incubate for 5-10 minutes to separate 
beads from solution;
4. Aspirate the cleared solution from the reaction plate and discard;
5. Dispense 200 μL of 85% ethanol to each well of the reaction plate and incubate for 
30 seconds at room temperature; aspirate out the ethanol and discard; repeat for a 
total of two washes;
6. Place the reaction plate on bench top to air-dry; the plate should be left for10-20 
minutes to allow complete evaporation of residual ethanol that may inhibit the 
subsequent reactions;
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7. Add 40 μL of dd H2O to each well of the reaction plate and mix in order to elute 
purified PCR product from the beads;
8. Transfer the purified products to a new plate.
This process has been automated and optimized by using the Biomek 3000 (Beckman 
Coulter) (Fig. 15). This instrument is an automated laboratory work station fully 
compatible with Agencourt AMPure.
As for the Biomek NXP, Biomek 3000 automates many processes. This instrument has 
a mechanic alarm that moves on 3 axes (X, Y, Z) mono and multichannel pipettes (P20, 
MP20, P200, MP200, P1000) besides the gripper tool that picks up and dislocates the 
plates. On the worktop there is space to accommodate the magnetic support as well as 
containers for reagents, plates, tips and waste. User-friendly software facilitates 
tailoring each protocol to specific requirements, or building new protocols from 
scratch. The user must have the material correctly placed on the worktop, as indicated 
on the program, and start it.
 Figure 15. Biomek 3000 
(Beckman Coulter).
Purified DNA fragments were quantified in order to settle the suitable quantity of DNA 
to use in the subsequent sequencing reaction. DNA yield was determined by 2% 
agarose gel analysis. The amount of loaded DNA sample was estimated by visual 
comparison of the band intensity with that of the standards (GeneRuler™ 100 bp DNA 
Ladder, Genenco); DNA quantity for a correct sequencing reaction is 10 ng per 100 bp. 
Purified PCR products were stored at 4 °C until their use.
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4.1.5 Sequencing analysis
Sequencing a DNA fragment amplified by PCR allows its nucleotide sequence to be 
determined, individualizing the possible presence of a variation. The most commonly 
used approach is the dideoxy chain termination method (Sanger method) [123]. The 
key principle of the Sanger method is the use of dideoxynucleotide triphosphates 
(ddNTPs) as DNA chain terminators: they are analogues of the normal dNTPs, but differ 
in that they lack a hydroxyl group at the 3’ carbonposition as well as at the 2’ carbon. 
Lacking this group, any ddNTP that is incorporated into a growing DNA chain cannot 
participate in phosphodiester bonding at its 3’ carbon atom, thereby causing abrupt 
termination of chain synthesis. Competition for incorporation into the growing DNA 
chain between a ddNTP and its normal dNTP analogue results in a population of 
fragments of different lengths. The technique requires a single-stranded DNA template, 
a DNA primer and a sequencing kit containing DNA polymerase, dNTPs and the four 
ddNTPs labeled with fluorescent dyes, each of which with different wave lengths of 
fluorescence and emission.
Figure 16. Schematic representation
 of the automated DNA 
sequencing with capillary 
electrophoresis (www.ap-
pliedbiosystem.com).
The newly synthesized and labeled DNA fragments 
are heat denatured and separated by size by capillary 
electrophoresis (CE). During CE, the DNA fragments 
are electrokinetically injected into capillaries filled 
with a high resolution polymer.
High voltage is applied so that the negatively charged 
DNA fragments move through the polymer toward 
the positive electrode. CE can resolve DNA molecules 
that differ in molecular weight by only one nucleotide. 
Shortly before reaching the positive electrode, the 
fluorescently labeled DNA fragments move throught 
he path of a laser beam that causes the dyes on the 
fragments to fluoresce. An optical detection device 
detects the fluorescence; specific software converts 
the fluorescence signal to digital data and records 
them (Fig. 16). Since each dye emits light at a different 
wavelength when excited by the laser, all four colors, 
and therefore, all four bases, can be detected and 
distinguished in one capillary injection (Fig. 17).
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Figure 17. Electropherogram (www.appliedbiosystem.com).
4.1.6 Sequencing reaction protocol
The sequencing reaction was performed by using the BigDye Term v1.1 Cycle Seq Kit 
(Applied Biosystems).
Sequencing protocol involved the use of:
•  1 μL of 10 μM primer forward or reverse;
•  1 μL of DNA sequencing Mix;
•  1μL of BigDye® Terminator v1.1 5X Sequencing Buffer;
•  DNA quantity established following the confirmation of PCR products on the
agarose gel (usually 1 μL of amplified DNA was used);
•  H2O to a final volume of 10 μL.
Each amplicon of the FN3K gene was sequenced on both strands; therefore two 
sequencing reactions, one with primer forward and the other with primer reverse, 
were performed. The reaction plate with the sequencing mix was automated using 
Biomek 3000 (Beckman Coulter).
For the sequencing reaction the following program on the thermalcycler was 
performed:
• 25 cycles, each one composed of: 96 °C for 10 seconds (DNA denaturation), 50 °C for 
5 seconds (primer annealing), 60 °C for 4 minutes (DNA extension).
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4.1.7 Purification of sequencing reaction products
It was necessary to purify the sequencing reaction products in order to remove unin-
corporated dye terminators and all the other reagents and by-products. Removal of 
unincorporated dye-terminators is required prior to capillary electrophoresis, because 
they can cause a “background noise” which makes the electropherograms unreadable.
The CleanSEQ Sequencing Reaction Clean-Up has proven an efficient and highly 
effective dye-terminator removal system with the ABI 3730 sequencer. This system 
utilizes Agencourt’s patented SPRI™ para-magnetic bead technology as in the AMPure 
purification process previously described.
Also in this case, the process is automated through Biomek 3000 (Beckman Coulter).
The protocol can be performed directly in the thermal cycler plate. CleanSEQ contains 
magnetic particles in an optimized binding buffer to selectively capture sequencing 
extension products, whereas unincorporated dyes, nucleotides, salts and contaminants 
are removed using a simple washing procedure.
The CleanSEQ procedure is performed in 7 steps:
1. Gently shake the CleanSEQ bottle to re-suspend any magnetic particles that may 
have settled. Add 10 μL of CleanSEQ to the reaction plate;
2. Add 42 μL of 85% ethanol to the reaction plate; pipette the mix 7 times;
3. Place the reaction plate onto magnetic support for 3 minutes to separate beads from
 solutions;
4. Aspirate the cleared solution from the reaction plate and discard;
5. Dispense 100 μL of 85% ethanol and incubate at room temperature for at least 30
seconds, then aspirate out the ethanol and discard; repeat for a total of 2 washes;
6. Let the reaction plate air-dry for 10 minutes at room temperature;
7. Add 40 μL of dd H2O and incubate the plate for 5 minutes at room temperature and
then transfer samples into a new clean reaction plate.
Figure 18. Schematic representation of CleanSeq purification.
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4.1.8 Sequencing 
Samples preparation
For DNA sequencing a 48-capillary 3730 DNA Analyzer (Applied Biosystems) instrument 
was used. Once purified, samples containing the sequencing reactions were prepared 
on a special plate for multi-channel electrophoresis runs. This plate was formed by 96 
wells; purified sequences were added in alternate rows since the 48 capillaries enter 
simultaneously in different wells. Two microliters of purified products together with 
8 μL of deionized formamide were placed in each well. The plate was covered with 
a rubber mat and centrifuged to bring the samples down to the bottom of the wells. 
Samples were denatured at 95 °C for 2 minutes on a thermal cycler and then incubated 
at -20 °C for at least 5 minutes.
Samples loading
Before loading the plate in the instrument, the worksheet showing the order of 
samples was entered in the computer. The first step was to appoint the plate with the 
“bar code” present on its side, together with the date of the transaction. The work-
sheet is a table in which rows represent the name of wells and columns the name of 
the sample, the protocol type and the reading type to be used. The plate was then 
inserted in the instrument: the 48 samples placed in alternating columns were 
analyzed first.
4.1.9 Software for sequence analysis
After the electrophoretic run and the acquisition of data by the analyzer, each DNA 
fragment sequence could be viewed on the computer screen: the four bases, 
labeled with different fluorophores, were detected and represented as peaks of four 
colors (green for adenine, blue for cytosine, black for guanine and red for thymine). 
Raw data analysis was performed by using the “Sequencing Analysis” software (Fig. 
19), designed to base-call, trim, display, edit, and print DNA sequencing data generated 
from the genetic analyzer; this step allowed to check if the procedure was successful or 
if the electrophoretic run had to be repeated. Moreover, this software provided 
multiple metrics (sample score, read length, signal-to-noise values) that help pinpoint 
the cause of data failure.
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Figure 19. “Sequencing Analysis” 
interface: the software 
was used to observe 
DNA sequences.
By using the SeqScape®software (Fig. 20), all the variations (deletions, insertions, 
mismatches, heterozygous bases, and heterozygous insertion/deletions) between the 
reference genomic sequence and each subject sample sequence were detected.
Software examines the quality of each forward and reverse trace and forms an 
accurate consensus call. Variations between the consensus and the reference sequence 
are reported as mutations in the Mutations report. All analysis in SeqScape®software 
occurred in a project; before creating a project, a project template containing a 
reference data group, analysis defaults and display settings was created. Once a project 
was created, the project template was used recurrently. As for the “Sequencing 
Analysis” software, the sequence was represented by a succession of peaks character-
ized by four different colors, one for each nucleotide. A peak overlap (identified by 
letter N) showed the presence of two different nucleotides in the same position and, 
therefore, the presence of a variant in the heterozygous state. If the alteration was 
present in the homozygous state, a different peak in comparison with the reference 
sequence was found: however, the change was signaled by the software. The existence 
of an insertion or a deletion in the sample was characterized by the presence of a 
complicated pattern of overlapping peaks from the site of the alteration because of a 
different positioning between the two strands. The presence of any genetic variant was 
always verified also on the complementary strand (3’ —> 5’).
 Figure 20. SeqScape® interface:
the software was used 
to identified polymor-
phisms/mutations by 
comparing the DNA 
fragment of interest 
with the reference 
sequence.
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Denaturing high performance liquid chromatography (DHPLC) is a variant of hetero-
duplex analysis [124] and has emerged as one of the most versatile technologies for 
the analysis of genetic variations [125]. DHPLC compares two chromosomes as a mix-
ture of denatured and reannealed PCR amplicons. When the PCR amplicon does not 
contain a mutation, the sense strand and the anti-sense strand of the PCR amplicons 
are completely complementary to each other. In this case, the molecule is referred to 
as a homoduplex. When a patient is heterozygous for a mutation, the mutant sense 
and antisense strands will not only form a homoduplex, but also heteroduplices with 
their corresponding wild type sense and anti-sense strands upon re-naturation of the 
denatured PCR product. The physicochemical difference between a homoduplex and 
heteroduplices can be detected by HPLC using a reversed-phase chromatography 
column with an affinity to double-stranded DNA. The differential retention of homo- 
and heteroduplex DNA on the column after partial denaturation indicates the presence 
of a mutation (Fig.21).
4.2 Denaturing High Performance Liquid Chromatography (DHPLC) analysis
Figure 21. Schematic 
representation of sepa-
ration of hetero-
duplexes from homo-
duplexes under partially 
DHPLC conditions for 
mutation detection.
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The temperature of the column determines sensitivity, and the optimal temperature is 
predicted by a mathematical formula based on the amplicon sequence; the output of 
this formula can be calculated using a computer program [126]. The stationary phase 
present in the column is electrically neutral or hydrophobic; DNA fragments that are 
negatively charged, cannot adsorb to the column’s matrix by themselves. Therefore, a 
“bridging” molecule is needed to help the adsorption of DNA fragments to the 
stationary phase. Such a molecule is triethylammonium acetate (TEAA), that binds on 
the one hand to DNA via its positively charged ammonium group, while it also inter-
acts with the hydrophobic column material via its hydrophobic ethyl groups; this way it 
builds a bridge between the column material and the nucleic acid. Separation of 
nucleic acids bound to the column is achieved at an optimized temperature by 
increasing the concentration of an organic solvent (e.g., acetonitrile) in the elution 
buffer, which competes with the hydrophobic interactions between the column and 
TEAA, resulting in the elution of the nucleic acid [125].
The presence of genetic variants found in the FN3K gene of diabetic patients by direct 
sequencing was verified in control subjects by using DHPLC technique. Exons 1 and 4 of 
the FN3K gene were amplified using protocols described in the section “DNA
 Amplification”. PCR products were denatured at 95 °C for 10 minutes and allowed to 
cool to 25 °C for the formation of homo- and heteroduplices. DHPLC was carried out 
using a Transgenomic DHPLC WAVE-MD 4000 Plus instrument and a DNASep column 
with buffer A (0.1 MTEAA solution in water pH 7.0) and buffer B (0.1 M TEAA solution 
in water 25 % acetonitrile pH 7.0). Elution of DNA from the column was determined by 
adsorbance at260 nm. The optimum temperatures for analysis of each fragment were 
predicted with the Navigator™ software (Transgenomic) and confirmed empirically. 
DHPLC conditions used for the analysis of each amplicon are described in Table 3: each 
amplicon was screened at different temperatures.
The heterozygous profiles were identified by visual inspection of the chromatograms 
on the basis of the appearance of additional, earlier-eluting peaks; corresponding 
homozygous profiles showed only one peak. Where necessary, samples were analyzed 
both alone and with the addition of 50 % wild-type DNA to ensure the detection of 
homozygous mutations. Samples displaying abnormal eluition profiles were re-
amplified and subjected to direct sequencing.
 Table 3. DHPLC conditions for the
analysis of the 2 ampli-
cons of the FN3K gene.
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4.3 RNA ANALYSIS
4.3.1 RNA extraction
RNA was extracted using the PAXgene Blood RNA System (PreAnalytiX), consisting of 
a blood collectiontube (PAXgene™ Blood RNA Tube) and nucleic acid purification kit 
(PAXgene Blood RNA Kit, QIAGEN).
For the extraction, 2.5 mL of whole blood of subjects of interest were collected in a 
PAXgene™ Blood RNA Tube. RNA was extracted using the manual procedure as 
described below:
1. PAXgene™ Blood RNA Tube was centrifuged for 10 minutes at 3000 x g using a
swing-out rotor;
2. The supernatant was removed by pipetting and the pellet was resuspended in 4 mL
RNase-free water;
3. The pellet was dissolved by vortexing, and centrifuged for 10 minutes at 3000 x g;
4. The supernatant was removed and discarded by pipetting; 
5. The pellet was resuspended in 350 µL Buffer BR1 and dissolved by vortexing;
6. The sample was placed in a 1.5 ml microcentrifuge tube, and 300 µL Buffer BR2 plus
40 µL proteinas K were added;
7. After vortexing for 5 minutes, the sample was incubated for 10 minutes at 55°C;
8. The lysate was then placed into a PAXgeneShadder spin column (lilac) placed in a 
2 mL processing tube, and centrifuged for 3 minutes at 10000 x g;
9. The entire supernatant of the flow-through fraction was transferred to a fresh 1.5 mL
microcentrifuge tube without disturbing the pellet in the processing tube;
10. 350 µL of ethanol (100%) were added, and 1-2seconds centrifugation was 
performed to remove drops from the inside of the tube lid;
11. 700 µL of sample were pipetted into a PAXgene RNA spin column placed in a 2 mL
processing tube and centrifuged for 1 minute at 10000 x g. The spin column was 
then placed in a new 2 mL processing tube and the old processing one containing 
flow-through was discarded;
12. 350 µL of Buffer BR3 were added into the PAXgene RNA spin column and 
centrifuged for 1 minute at 10000 x g. The spin column was then placed in a new  
2 mL processing tube and the old processing one containing flow-through was 
discarded;
13. 80 µL of DNase incubation mix (10 µL of DNase I stock solution + 70 µL of Buffer
RDD) were added directly onto the PAXgene RNA spin column membrane, and 
placed on the bench top (20-30°C) for 15 minutes;
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14. 350 µL of Buffer BR3 were added into the PAXgene RNA spin column and 
centrifuged for 1 minute at 10000 x g. The spin column was then placed in a new 
2 mL processing tube and the old processing one containing flow-through was 
discarded;
15. 500 µL of Buffer BR4 were added into the PAXgene RNA spin column and 
centrifuged for 1 minute at 10000 x g. The spin column was then placed in a new 
2 mL processing tube and the old processing one containing flow-through was 
discarded;
16. Another 500 µL of Buffer BR4 were added into the PAXgene RNA spin column and
centrifuged for 3 minutes at 10000 x g;
17. The PAXgene RNA spin column was placed in a 1.5 mL microcentrifuge tube, and
40 µL of Buffer BR5 was added directly onto the PAXgene RNA spin column 
 membrane. 
18. After 1 minute centrifugation at 10000 x g, the elution step (step 17) was repeated;
19. The eluate was incubated for 5 minutes at 65°C and then immediately chilled 
 on ice.
The RNA sample obtained with this procedure was stored at -80°C until its use.
Figure 22. Schematic representation of
the manual PAXgene Blood RNA 
procedure.
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4.3.2 Reverse Trancription
Reverse transcription reaction was prepared in a total volume of 20 μL adding the 
following reagents:
• 1 μg RNA solution
• 1 μL40 μM random primers
• Nuclease free H2O for a total volume of 11 μL
The reaction was incubated at 65°C for 5 minutes and at room temperature for 
additional 5 minutes, to allow extension of the primers. Then were added:
• 2 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 4 μL 25 mM MgCl2
• 1 μL 2.5 mM dNTPs
• 1 μL RNAse inhibitor
• 1 μL MuLV reverse transcriptase (Roche)
The sample was incubated at 42°C for one hour. The enzyme was then inactivated 
heating the sample at 95°C for 5 minutes. 
The cDNA sample obtained with this procedure was stored at -20°C until its use.
4.3.3 cDNA Amplification
cDNA was amplified by PCR. Primers were designed to amplify the region containing 
the new mutations found. The main characteristics are listed in Table 4.
Table 4. Shows the length of PCR products and some characteristics of the primers (sequence, melting,
temperature) used in each PCR amplification.
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Each PCR reaction was performed in a total volume of 25μL. 
PCR mixture to amplify the fragments with the c.2 T>A, and both c.559 C>T and 
c.716 A>G mutations contained:
• 16,1 μL H2O
• 2,5 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 1 μL 25 mM MgCl2
• 2 μL 2.5 mMdNTPs
• 1 μL 15mM primer forward
• 1 μL 15mM primer reverse
• 0,4 μL FastStartTaq® DNA Polymerase
• 1 μL cDNA
PCR mixture to amplify the fragment with c.465 G>A mutation contained:
• 16,6 μL H2O
• 2,5 μL PCR Buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl)
• 0.5 μL 25 mM MgCl2
• 2 μL 2.5 mMdNTPs
• 1 μL 15 mM primer forward
• 1 μL 15 mM primer reverse
• 0,4 μL FastStartTaq® DNA Polymerase
• 1 μL cDNA
The program on thermal cycler was settled as follow:1 cycle at 95 °C for 4 minutes; 
95 °C for 30 seconds, 57°C for 30 seconds; 72 °C for 30 seconds, for35 cycles; 1 cycle at 
72 °C for 10 minutes.
For each amplification protocol, a negative control consisted of a PCR mixture aliquot 
with no cDNA added was used, to give indication of the presence or absence of 
contamination in the reaction. Once the amplification was completed, 2% agarose gels 
were prepared in order to test the quality of the PCR products.
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4.4 miRNA ANALISYS
4.4.1 Patients
Ten subjects were selected from a randomized double-blind, parallel study undertaken 
with 200 men with T2DM, recruited after screening 412 Caucasian patients at Diabetes 
Research Centre in Kingston upon Hull, UK. Subjects aged between 45 to 75 years with 
a total testosterone level ≤12 nmol/L and normal gonadotrophins. They were random-
ized and administered either 30g soy protein with 66mg of isoflavones (SPI) per day, or 
30g soy protein alone without isoflavones (less than 300 parts per billion) (SP) for 12 
weeks.
Selected subjects were all under active treatment with soy and isoflavones.
All patients were on stable medications for their T2DM, hyperlipidemia and hyperten-
sion for at least 3 months prior to the study. Patients with significant hepatic or renal 
impairment, who were allergic to soy products, receiving testosterone replacement or 
who had received antibiotics 3 months prior to the study were excluded.
At randomization and during study visits, subjects were instructed to maintain their 
level of physical activity throughout the study. In addition, they were required to avoid 
food products containing soy, alcohol, vitamin or mineral supplementation, and over-
the-counter medications. Dietary reinforcement was undertaken at each visit, together 
with measurement of plasma isoflavone levels to ensure compliance. Compliance with 
study preparation was calculated by counting the returned bars. All subjects gave their 
written informed consent. The study was given ethical approval by the Research Ethics 
Committee (East Yorkshire & North Lincolnshire Research Ethics Committee, 
ref:09/H1304/45).
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4.4.2 miRNA extraction
RNA isolation was performed from plasma samples using the mirVana™ PARIS™ Kit (Life 
Technologies). The procedure consisted of the following steps:
1. each sample was thawed; 350 µL of plasma sample were placed in a 1.5 mL tube
together with 350 µL of denaturing solution (containing 2-mercaptoethanol) and 
incubated on ice for 5 minutes;
2. 6 µL of 1:200 dilution stock solution of C. elegans miR-93-3p spike-in standard were
added to the each sample;
3. 700 µL of acid-phenol:chloroform were added and mixed by vortexing for 30 
seconds;
4. a centrifugation at 10000 g for 5 minutes at room temperature was performed;
5. the aqueous layer was removed without touching the interphase or organic layers
and placed in a new 1.5 mL tube;
6. the same volume of RNase-free water removed in the previous step, was added to
the interphase or organic layers, and mixed by vortexing for 30 seconds;
7. a centrifugation at 10000 g for 5 minutes at room temperature was performed;
8. the aqueous layer was removed and combined with the previous one collected;
9. 1.25 volumes of 100% ethanol were added to the combined aqueous phases and
mixed thoroughly;
10. 700 µL lysate/ethanol mix were added to a filter column placed in a collection tube;
11. a centrifugation at 10000 g for 30 seconds at room temperature was performed;
12. the flow through was discarded, and 700 µL of miRNA wash solution 1 were added;
13. a centrifugation at 10000 g for 15 seconds at room temperature was performed;
14. the flow through was discarded, and 500 µL of miRNA wash solution 2/3 were
added;
15. a centrifugation at 10000 g for 15 seconds at room temperature was performed;
16. steps 14) and 15) were repeated;
17. the flow through was discarded and the sample was centrifuged at 10000 g for 
1 minute;
18. the column was placed in a fresh1.5 mL tube and 10µL of preheated to 95°C 
RNase-free water were added to the filter to elute miRNA;
19. a centrifugation at 10000 g for 30 seconds at room temperature was performed;
20. steps 18) and 19) were repeated.
The 20 µL of RNA sample obtained with this procedure were stored at -80°C until
required. 
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4.4.3 Screening of miRNA
miRNA detection experiments were performed on Serum/Plasma Focus microRNA PCR 
Panel I+II (V6.0) using the miRCURY Locked Nucleic Acid (LNA™) Universal RT microRNA 
PCR System  (Exiqon). This microRNA-specific, LNA™-basedsystem is designed for sensi-
tive and accurate detection of microRNA by quantitative real-timePCR using SYBR® 
Green. The method is based on universal reverse transcription (RT) followed by real-
time PCR amplification with LNA™ enhanced primers (Fig. 23). 
Figure 23. Schematic outline of the miRCURY LNA™ Universal RT microRNA System. A polyA tail is added
to the mature microRNA template (step 1A). cDNA is synthesized using a polyT primer with 
a 3’ degenerate anchor and a 5’ universal tag (step 1B). the cDNA template is then amplified 
using microRNA-specific and LNA™-enhanched forward and reverse primers (step 2A). SYBER® 
Green is used for detection (step 2B).
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4.4.4 cDNA synthesis (RT)
The reverse transcription reaction was performed in a total volume of 40 μL. 
The reaction setup contained: 
• 20 μL nuclease free water;
• 8 μL 5x Reaction buffer;
• 4 μL Enzyme mix;
• 8 μL RNA template (5 ng/μL)
The RT-PCR was settled as follows: incubated at 42°C for 60 minutes, heat-inactivated 
at 95°C for 5 minutes, and immediately cooled to 4°C using a thermalcycler (GeneAmp® 
PCR System 9700, AppliedBiosystems). The cDNA was then stored at -80°C or used for 
PCR reaction. 
4.4.5 Real-time PCR amplification 
Before starting, the cDNA, the nuclease free water and the ExiLENT SYBR® Green 
master mix 2x concentrated were placed on ice for 15-20 minutes, and plates were 
spinned down in a plate centrifuge. The qPCR protocol for two plates of 96 wells was 
performed as follows:
• 1050 µL of ExiLENT SYBR® Green master mix were combined with 1039.5 µL of
nuclease free water and10.5 µL of cDNA;
• 10 µL of PCR Master mix:cDNA mix were added to each well. 
The experiment can be paused at this point and stored, protected from light, at 4°C for 
up to 24 hours. 
The amount of PCR product was detected by evaluating the level of fluorescence 
emitted by SYBR® Green. Quantitative PCR was carried out on a StepOnePlus™ 96-well 
Real-Time PCR instrument (Life Technologies) according to the following instruction: 
95°C for 10 minutes, 40 amplification cycles at 95°C for 10 seconds, 60°C for 1 minute. 
Quantitative PCR reactions were concluded with a melting curve to disassociate the 
SYBR Green dye from amplification products, allowing the specificity of the amplifica-
tion to be assessed. 
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4.4.6 Serum/Plasma Focus miRNAPCR Panels I+II
Serum/Plasma Focus microRNA PCR Panels I+II (V6.0) (Exiqon) cover the analysis of 179 
human miRNAs and contain: 179 LNA™ primer sets for the amplification of human 
micro RNA; 2x3 inter plate calibrators, 5 RNA spike-in control primer sets; two blank 
wells, one in each plate (Fig. 24, 25). 
Figure 24. Serum/Plasma Focus microRNA PCR Panel I, 96-well plate layout.
Figure 25. Serum/Plasma Focus microRNA PCR Panel II, 96-well plate layout.
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4.4.7 miRNA measurement
For calibration between PCR plate runs were used inter-plate calibrators. Each panel 
contain three inter-plate calibrators assay (annotated as UniSp3IPC in the plate layout, 
Fig. 24, 25). Each of these wells contain pre-aliquoted primer pair and DNA template, 
with a minimal variation from well-to-well and from plate to plate. 
Inter-plate calibration (IPC) was performed manually using the IPC assay replicates as 
follows. For each plate was verified that the replicates had Ct standard deviation within 
0.5. The average of the replicates for each plate, the overall average (average of IPC 
values from all plates) were calculated. The calibration factor was calculated as the dif-
ferences between plate average and overall average for each plate (calibration factor= 
IPC plate – IPC overall). Finally, each plate was calibrated by subtracting the calibration 
factor from all Ct values in the plate. Threshold for expression was set as Ct<37, and 
miRNAs not expressed under this criteria were removed from consideration. 
Quantification of relative miRNA expression was performed with the comparative Ct 
method using the formula: 2^-ΔΔCT where ΔCT = [(CT gene of interest-CT reference 
gene) sample A - (CT gene of interest-CT reference gene) sample B] by using cel-miR-
93-3p as the reference gene.
4.5 Statistical analysis
Student’s t-test was used to examine the differences between two groups and ANOVA 
test to evaluate differences between more groups. Differences were considered 
significant for P-value <0.05. Statistical analysis were performed using GraphPad Prism® 
6 sofware. 
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5. RESULTS
5.1 Fructosamine 3-kinase screening in an Italian population of diabetic 
subjects
A total 150 diabetic patients and 33 healthy controls were analyzed for the FN3K gene. 
Diabetic subjects were recruited in different times at Policlinic Hospital of Padua and 
divided into two different cohorts: cohort 1 and cohort 2. Diabetic state was assessed 
using WHO criteria [24], according to which fasting plasma glucose level had to be 
more than 126 mg/dL. The mean values of HbA1c were above the reference threshold 
(4-6% in healthy people) [68] and correlates with presence of diabetic complications. 
The same criteria were used to exclude the presence of diabetes in healthy controls. 
5.1.1 Analysis of FN3K promoter region in cohort 1
Cohort 1 was made up of 70 patients, 35 T1DM and 35 T2DM, and 33 healthy controls. 
This cohort was previously analyzed for the FN3K gene [76]. 
The baseline characteristics of patients and control subjects are reported in Table 5.
 Table 5. Clinical characteristic of
cohort 1. The data are 
presented as mean ± 
standard deviation.
The first screening analyzed the coding part of the FN3K gene (6 exons and correspond-
ing intron/exon boundaries), identifying two new mutations (c.716 G>A, c. 559 C>T) 
and confirming the presence of some variants previously reported [76].
Here the molecular investigation of FN3K gene was completed by the analysis of its 
promoter region. The portion of promoter region was -470 bp with the respect of ATG. 
PCR conditions were optimized and the fragment was amplified following protocol 
described in the section “DNA amplification” of Material and Methods. PCR products 
were purified and both forward and reverse strands were analysed though direct 
sequencing. 
Genotypes and allele frequencies distributions of genetic variants detected in the 
promoter region of FN3K gene in T1DM, T2DM and controls are reported in Table 6.
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 Table 6. Genotypes and allele
frequencies of FN3K 
promoter genetic variants 
identified in cohort 1.
The values for genotypes and for the rare alleles are frequencies.
T1DM, type 1 diabetes; T2DM, type 2 diabetes; Controls, healthy subjects.
rs, RefSNP ID: http://www.ncbi.nlm.nih.gov/snp/. 
The ‘‘+’’ symbol indicates the wild type allele and ‘‘del’’ the allele characterized by the deletion.
The presence of two polymorphisms, the c.-385A>G (rs3859206) and the c.-232A>T 
(rs2256339), known to be associated with the FN3K enzymatic activity in erythrocytes 
[71] was evaluated. 
The allelic frequencies for each polymorphism were calculated in all groups. Hardy-
Weinberg equilibrium (HWE) of the identified polymorphisms for the entire population 
(103subjects) and for each subpopulation (T1DM, T2DM, Controls) was estimated using 
the χ2-test. Results were considered significant for p-values <0.05. 
The statistical analysis performed on our cohort indicates that the population was in 
HWE for the polymorphism c.-385A>G, while for c.-232A>T, T1DM patients and total 
population had values above the critical threshold of 3.84, considered at a level of 
significance of 5%, pointing out that HWE is not respected (Table 7). 
 Table 7. Chi-square values 
calculated in diabetic and 
control populations
Furthermore, the screening allowed the identification of two new variants, the
c.-429delATCGGAG and the c.-421C>T, in one patient with T1DM, reported here for the 
first time.
57
5.1.2 Analysis of FN3K gene in cohort 2
Cohort 2 was recruited in a second time and was made up of 80 patients with T2DM. 
For all enrolled subjects more clinical informations were available: BMI, waist, presence 
of hypertension, dyslipidemia, microalbuminuria, cerebral macroangiopathy, retinopa-
thy and peripheral arterial disease. Moreover, several biochemical parameters were 
measured: HbA1c, ADMA, arginin, p-mda, er-MDA, omocistein, vitamin A and vitamin 
E. The characteristics of patients belonging to cohort 2 are reported in Table 8.
Table 8. Clinical characteristic of cohort 2.
Data are expressed in mean + standard deviation where applicable.
All subjects were analyzed for the entire FN3K gene, all 6 exons with corresponding 
intro-exon boundaries and the promoter region. DNA was amplified with specific 
primers following protocol described in Material and Methods. PCR products were 
purified and both forward and reverse strands were analysed though direct sequencing. 
The screening identified 13 variants within the FN3K gene, 3 of them (c.2T>A,
IVS2-27A>G and c.465G>A) being never reported so far. Furthermore, variants
previously identified in a single patients with T1DM (c.-421C>T, c.-429delATCGGAG) 
were found in one subject with T2DM (Table 9). 
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The allelic frequencies for each polymorphism were calculated in all groups. HWE of 
the identified polymorphisms was estimated using the χ2-test. Results were considered 
significant for p-values <0.05. The statistical analysis performed on our cohort indicates 
that HWE for all detected polymorphisms was respected.
 Table 9. Genotypes and allele 
frequencies of FN3K
genetic variants identified 
in cohort 2.
The values for genotypes and for the rare alleles are frequencies.
T2DM, type 2 diabetes; Controls, healthy subjects.
rs, RefSNP ID: http://www.ncbi.nlm.nih.gov/snp/. 
The ‘‘+’’ symbol indicates the wild type allele and ‘‘del’’ the allele characterized by the deletion.
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5.1.3 Identification of FN3K genetic variants
The characterization of the FN3K gene though direct sequencing in both cohort 1 and 
2 revealed the presence of 15 different genetic variants reported in Table 10: 4 located 
in the promoter region; 7 in coding regions (exons 1, 2, 4, 5, 6); while 4 in non-coding 
portions (introns 2 and 4).
Of these 15 variants, 5 were unpublished variants, 2 were previously published by our 
group [76], while the remaining 8 were polymorphisms already reported in NCBI SNPs 
database.
 Table 10. List of FN3K genetic
variants identified in the 
studied groups.
a AA:aminoacid change
b RefSNP ID: http://www.ncbi.nlm.nih.gov/snp/
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5.1.4 Characterization of genetic variants
Variant c.-232 A>T 
The polymorphism c.-232 A>T was identified in the promoter region (Fig. 26 A). 
It was detected in heterozygous state in 92 patients (Fig. 26 B): of these 24 were T1DM, 
22 T2DM of cohort 1 and 46 T2DM of cohort 2. The homozygous state was detected 
in 35 patients (Fig. 26 C): of these .6 were T1DM, 7 T2DM of cohort 1 and 22 T2DM of 
cohort 2. 
The polymorphism was already described in literature (rs2256339 in the NCBI SNPs 
database).
Figure 26. Position of sequencing analysis of promoter region. The red arrow shows the position of the
variant c.-232 A>T: A) wild type (single red peak); B) heterozygous state (double peak); C) 
homozygous state (single green peak).
Variant c.-385 A>G
The polymorphism c.385 A>G was identified in the promoter region (Fig. 27 A). 
It was detected in heterozygous state in 83 patients (Fig. 27 B): of these 21 were T1DM, 
19 T2DM of cohort 1 and 43 T2DM of cohort 2. The homozygous state was detected 
in 40 patients (Fig. 27 C): of these 7 were T1DM, 8 T2DM of cohort 1 and 25 T2DM of 
cohort 2. 
The polymorphism was already described in literature (rs3859206 in the NCBI SNPs 
database).
Figure 27. Position of sequencing analysis of promoter region. The red arrow shows the position of the
variant c.385 A>G: A) wild type (single black peak); B) heterozygous state (double peak); 
C) homozygous state (single green peak).
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Variant c.-421 A>T and Variant c.-429delATCGGAG
These variants were identified in the promoter region (Fig. 28) in two patients one with 
T1DM of cohort 1 and one with T2DM of cohort 2 both in heterozygous state. The first 
one, c.-421 A/T, caused the substitution of an A with a T at position -421; while the 
second one, variant c. -429delATCGGAG, consisted of a 7 nucleotides deletion.
These variants were previously unpublished.
 Figure 28. Position of sequencing
analysis of promoter 
region. The red arrow 
shows the position of 
the variant c.-421 A>T. 
The green arrow 
indicates the starting 
point of the 
c. -429delATCGGAG 
deletion. The double 
peaks demonstrate the 
heterozygous state.
Variant c.2 T>A
Variant c.2 T>A was detected in heterozygous state in exon 1 (Fig. 29), in only a patient 
affected by T2DM: it changed the T forming the first triplette ATG for methionine, with 
an A. This variant causes the abolition of the translation starting site and probably the 
activation of a new starting site downstream the N-terminal region (p.Met1_Gln50del).
 Figure 29. Position of sequencing
analysis of exon 1. The 
red arrow shows the 
position of the variant 
c.2 T>A; the double 
peak demonstrates 
that it is present in 
heterozygous state 
(T/A).
62
Variant c.187 A>C
The polymorphism c.187 A>C was identified in exon 2 (Fig. 30): it didn’t change the 
deduced sequence of the protein (p.R63R).It was present in all the diabetic patients in 
homozygous state (C/C).
This polymorphism was already reported in literature (rs2253149 in the NCBI SNPs
database).
Variant IVS2+26 G>A in intron 2
The polymorphism IVS2+26 G>A was detected in intron 2 (Fig.31): it was presented in 
all diabetic subjects in homozygous state (A/A).
This polymorphism was already reported in literature (rs2253132 in the NCBI SNPs 
database).
 Figure 30. Position of sequencing
analysis of exon 2. The 
red arrow shows the 
position of the variant 
c.187 A>C; the single 
blue peak demon-
strates that it is present 
in homozygous state 
(C/C).
 Figure 31. Position of sequencing 
analysis of intron 2. The 
red arrow shows the 
position of the variant 
IVS2+26 G>A; the green 
peak demonstrates 
that it is present in 
homozygous state 
(A/A).
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Variant IVS2+31 A>T in intron 2
The polymorphism IVS2+31 A>T was identified in intron 2 (Fig. 32): it was detected in 
heterozygous state in 15 T2DM patients. 
This polymorphism was already reported in literature (rs2253131 in the NCBI SNPs 
database).
 Figure 32. Position of 
sequencing analysis of 
intron 2. The red arrow 
shows the position 
of the polymorphism 
IVS2+31 A>T; the 
double peak 
demonstrates that it is 
present in 
heterozygous state 
(A/T)
Variant IVS2-27 A>T in intron 2
The variant IVS2-27 A>T was identified in intron 2 (Fig. 33) in a single patients with 
T2DM in heterozygous state. This variant was previously unpublished and caused the 
substitution of a G with an A 27 nucleotides upstream exon 3. 
 Figure 33. Position of sequencing
analysis of intron 2. 
The red arrow shows 
the position of the
 variant IVS2-27 A>T; 
the double peak 
demonstrates that it is 
present in 
heterozygous state 
(T/A).
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Variant c.465 G>A
The variant c.465 G>A was identified in heterozygous state in exon 4 (Fig. 34) in only 
one patient with T2DM. It caused a synonymous substitution at codon 155 (p.P155=) of 
a proline, that is located few nucleotides from the splicing site region possibly altering 
the splicing process. This mutation was unpublished.
Variant IVS4-9-11delTTG 
The genetic variant IVS4-9-11delTTG was identified in intron 4 (Fig. 35 A): it consisted 
of a deletion of 3 nucleotides (TTG) and was found in 20 patients in heterozygous state 
(Fig. 35 B) and in one patient in homozygous state (Fig. 35 C). 
This polymorphism was already reported in literature (rs72318398 in the NCBI SNPs
database).
 Figure 34. Position of sequencing
analysis of exon 4. The 
red arrow shows the 
position of the variant 
c.465 G>A; the double 
peak demonstrates 
that it is present in
heterozygous state 
(G/A).
Figure 35. Position of sequencing analysis of intron 4. The variant IVS4-9-11delTTG is showed in: 
A) wild type state; B) heterozygous state; C) homozygous state. The red arrow shows the 
starting position of the deletion.
65
Variant c.559 C>T
Variant c.559 C>T was identified in exon 5 (Fig. 36) and caused a substitution of an 
arginine into a premature stop codon at codon 187 (p.R187*). It was found in on 
patient affected by T2DM (cohort 1) in heterozygous state. This variant was previously 
published by our group [76].
Variant c.716 A>G
The variant c.716 A>G was detected in exon 6 (Fig. 37) and caused the substitution of 
a tyrosine for a cysteine at codon 239 (p.Y239C). It was found in only one subject with 
T2DM (cohort 1) in heterozygous state. This variant was previously published by our 
group [76].
 Figure 36. Position of 
sequencing analysis of 
exon 5. The red arrow 
shows the position 
of the variant c.559 
C>T; the double peak 
demonstrates that it is 
present in 
heterozygous state 
(C/T).
 Figure 37. Position of 
sequencing analysis of 
exon 6. The red arrow 
shows the position 
of the variant c.716 
A>G; the double peak 
demonstrates that it is 
present in 
heterozygous state 
(A/G).
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Variant c.900 C>G 
The variant c.900 C>G was identified in exon 6 (Fig. 38): it caused a synonymous 
substitution  of serine at codon 300 (p.S300S). It was found in heterozygous state and 
in homozygous state respectively in the 38 and 30 patients with diabetes.
The polymorphism was already described in literature (rs1056534 in the NCBI SNPs 
database).
 Figure 38. Position of sequencing analysis of exon 6. The red arrow shows the position of the variant
c.900 C>G: A) wild type (single blue peak); B) heterozygous state (double peak); 
C) homozygous state (single black peak) .
 Figure 39. Position of sequencing
analysis of exon 6. The 
red arrow shows the 
position of the 
variant c.900 C>G. The 
green arrow indicates 
the polymorphism 
c.900 C>T previously 
described. Double 
peaks demonstrate the 
heterozygous state for 
both polymorphisms.
Variant c.906 C>T
The variant c.906 C>T was identified in exon 6 (Fig. 39) and caused the substitution of 
a C with a T at codon 302 without changing the amino acid (G302=). This variant was 
found in heterozygous state in 2 diabetic subjects with T2DM. 
This polymorphism was already described in literature (rs149413139 in the NCBI SNPs 
database).
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5.1.5 Screening of control subject using DHPLC 
DHPLC analysis was performed on 33 healthy control subjects in order to exclude 
presence of new mutations found in coding regions of diabetic patients: c.2 T>A, 
c.465 G>A. Analysis was conducted on PCR products of exons 1 and 4 on both control 
and diabetic subjects harboring mutations detected through direct sequencing. 
A previously sequenced sample without any mutation was used as internal control.
None of the mutations were never found in these control group ( Fig.40). 
Figure 40. DHPLC chromatograms for control subjects screening. Retention times of homoduplex and 
heteroduplex fractions are indicated on the x-axis. A) Analysis of the variant c.2 T>A: green 
double pick represent heterozygous sample. B) Analysis of the variant c.465 G>A: green 
double pick represent heterozygous sample.
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5.1.6 Genotype and phenotype correlation
Referring to the literature, a genotype composed by the combination of 
polymorphisms mostly associated with a variation in the enzymatic activity of 
FN3K in erythrocytes [71] and with a variation of HbA1c values [73] was considered. 
These polymorphisms are: rs3859206, rs2256339 (in the promoter region) 
and rs1056534 (in exon 6). T1DM subjects of cohort 1 were excluded since HWE 
was not respected for polymorphism rs2256339.
Thirteen genotypes have been identified and summarized in Table 11.
 Table 11. Genotypes and relative
frequencies in the 
studied groups.
The values for genotypes are frequencies.
Cohort 1, (n= number of T2DM subjects);Cohort 2, (n= number of T2DM subjects); Controls, (n= healthy subjects).
rs, RefSNP ID: http://www.ncbi.nlm.nih.gov/snp/. 
The genotypes GG at position -385, TT at position -232 and CC at c.900 have been 
associated with a better performance of the FN3K enzymatic activity [71]. Moreover, 
the latter has been also associated with lower HbA1c values [73]. 
The previous study performed on cohort 1 [76] confirmed the observation that 
patients carrying the CC allele for polymorphism c.900 C>G had lower HbA1c level 
compared with those presenting GG alleles. Adding the promoter region results,
 it was interesting to note that these patients presented also the GG genotype for 
the polymorphism -385A>G. 
The same result was found also on cohort 2 and on gathering cohort 1 to cohort 2 
(Total). Subjects carrying favorite alleles for the 3 mentioned polymorphisms, 
genotype A, displayed HbA1c values lower than those with genotype C (Fig.41).
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Figure 41. HbA1c concentration in Cohort 1 (A), Cohort 2 (B) and Total T2DM (C) subjects according to 
genotype A (green) and C (yellow). Genotypes composition are reported in Table 11. HbA1c 
values are expressed as mean + standard deviation. The number of patients for genotype is 
indicated in brackets.
However, the difference between glycated hemoglobin mean values and different 
genotypes was not statistically significant (Cohort 1 p= 0.1416; Cohort 2 p=0.3779; 
Total p=0.1749). 
According to the presence of microvascular (microalbuminuria and rethynopathy) or 
macrovascular (cerebral macroangiopathy and peripheral arterial disease) complica-
tions, patients of cohort 2 were subdivided into two groups. Patients belonging to the 
two groups were categorized based on genotypes and HbA1c mean values were 
compared. Genotypes represented by a single patient have been excluded from the 
analysis (Fig. 42). 
Figure 42. HbA1c concentration in Macrovascular (A) and Microvascular (B) groups according to
genotype. Genotypes composition are reported in Table 11. HbA1c values are expressed as 
mean + standard deviation. The number of patients for genotype is indicated in brackets.
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No statistically significant difference between glycated hemoglobin mean values and 
different genotypes have been observed using ANOVA test (Macro p= 0.6947; Micro 
p=0.4980). However, patients with macorvascularar complications displayed different 
genotypes from those with microvascular ones. 
Finally, the C allele of polymorphism in exon 6 (c.900 C>G, rs1056534) has been 
associated with progression of diabetic nephropathy and cardiovascular morbidity 
and mortality [74]. Seventeen subjects belonging to cohort 2 presented nephropathy. 
However, only 3 patients out of the 17 with nephropathy presented the CC alleles 
for the polymorphism in exon 6, highlighting the absence of a significant association 
(p=0.7305) of the polymorphism with diabetic nephropathy in this cohort.
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5.2 Study of new mutations identified
5.2.1 In silico analysis of new variants
New variants identified by sequencing were analysed using software Mutation Taster 
algorithm [127] to explore the likelihood of associated disruption of the FN3K protein 
structure and concomitant disease induction. Mutation Taster is a free web-based 
application for rapid evaluation of disease causing potential of DNA sequence 
alterations. MutationTaster integrates information from different biomedical databases 
and uses established analysis tools [127]. Analyses comprise evolutionary conservation, 
splice-site changes, loss of protein features and changes that might affect the amount 
of mRNA. Test results are then evaluated by a naive Bayes classifier, which predicts the 
disease potential.
The deleterious effects of missense mutations on FN3K protein were confirmed using 
Polyphen2 [128] and SIFT [129] in silico softwares. 
Among 7 new genetic variants, 4 were found to be pathogenetic: c.2 T>A; c.465 G>A; 
c.559 C>T and c.716 A>G. 
 Figure 43. Mutation Taster 
prediction output for 
variant c.2 T>A.
 Figure 44. Mutation Taster 
prediction output for 
variant IVS2-27 A>T.
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 Figure 45. Mutation Taster 
prediction output for 
variant c.465 G>A.
 Figure 46. Mutation Taster
prediction output for 
variant c.559 C>T.
 Figure 47. Mutation Taster 
prediction output for 
variant c.716 A>G.
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5.2.2 RNA analysis
In order to confirm hypothesis on pathogenicity of these four mutations (c.2 T>A, 
c.465 G>A, c.559 C>T and c. 716 G>A) found at genomic level, an RNA expression study 
was performed. All subjects carrying a predicted pathological mutation, a total of 4 
subjects, have been processed. RNA was extracted from peripheral blood using 
Paxgene Blood RNA kit. Coding DNA (cDNA) was obtained retro-transcribing mRNA 
using MuLV reverse transcriptase enzyme. A cDNA previously sequenced and not 
carrying any mutations was used as control subject. cDNA was amplified by PCR with 
specific primers flanking regions containing alterations (see Materials and Methods). 
 Figure 48. cDNA amplification fragment containing
c.2 T>A mutation. 
Length of the amplicon was 169 bp.
 Figure 49. cDNA amplification fragment containing
c.465 G>A mutation. 
Length of the amplicon was 167 bp.
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 Figure 50. cDNA amplification fragment containing
c.559 C>T and c.716 G>A mutations. 
Length of the amplicon was 487 bp.
The analysis didn’t find out any changes in amplicons lengths for all variants taken into 
consideration compared to control sample.
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5.2.3 Familial study of some new genetic variants in the FN3K gene
Family 1
Here is described the family harbouring the c.716 C>T (p.Y239C) mutation in the FN3K 
gene (Fig. 51). The index case (II:3) is a 61 year-old woman with a history of T2DM. 
Three members of the index case family were available for the genetic test: her 58 
year-old brother (II:1) and two sisters, one of 59 years old (II:2) and the elder sister 
of 62 years old (II:4) (Fig. 51).
All 3 subjects had been screened for the presence of the mutation c.716 C>T in exon 6. 
Moreover, they were screened also for the presence of the 3 polymorphisms 
associated with some peculiar aspects of diabetes: c.-385 G>A (rs3859206) and 
c. -233 T>A (rs2256339) in the promoter region, and c.900 G>C (rs1056534) in exon 6. 
Results of genetic testing are summarized in Table 12.
Figure 51. Pedigree of family 1 with the Y239C mutation in the FN3K gene.
 Table 12. Results of FN3K 
molecular analysis of 
family 1.
76
Two out of three siblings carrying the mutation c.716 A>G. It is interesting to note 
that all subjects carrying the mutation presented the same genotypes for the other 
polymorphisms examined. 
All subjects were clinically investigated and, except for subject II:2 that has T1DM, the 
remaining three presented T2DM. Clinical data are listed in Table 13.
 Table 13. Clinical characteristic of family 1.
The RNA expression study was performed on mutated subjects. As for the index case, 
the analysis didn’t find out any change in the amplicons lengths.
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Family 2
Here is described the family with the c.559 C>T (p.R187*) mutation in the FN3K gene 
(Fig. 52). The index case (II:2) is a 75 year-old woman with a history of T2DM. Her 
brother (II:1), a 66 year-old man without diabetes symptoms, gave his consent for the 
genetic test. 
Figure 52. Pedigree of family 2 with R187* mutation in the FN3K gene.
Proband’s brother has been screened for the presence of the mutation c.559 A>G in 
exon 5. Moreover, we tested him also for the presence of the 3 polymorphisms 
associated with peculiar aspects of diabetes: c.-385 G>A (rs3859206), c.-233 T>A 
(rs2256339) and c.900 G>C (rs1056534). Results of genetic testing are summarized in 
Table 14.
 Table 14. Results of FN3K 
molecular analysis of 
family 2.
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FN3K analysis pointing out that the proband’s brother (II:1) didn’t have the mutation 
c. 559 C>T. However, in this family, is interesting to note that siblings presented the 
same genotypes for the 3 polymorphisms, even if only the proband (II:2) has diabetes. 
All subjects were clinically investigated. Clinical data are listed in Table 15.
 Table 15. Clinical characteristic 
of family 2.
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5.3 Plasma profile of microRNAs after soy supplementation in patients 
with T2DM and subclinical hypogonadism
A total of 10 male T2DM subjects, with a total testosterone level ≤12 nmol/L and 
compensated hypogonadism, were analyzed to identify the differentially expressed 
miRNA in the peripheral plasma samples before and after treatment with soy and 
phytoestrogens. 
All patients were under active treatment with soy and isoflavons for twelve week and 
were divided into two groups: before (visit1) and after administration (visit 2). Plasma 
samples fromT2DM patients were collected on both occasions. Clinical characteristics 
of the individuals included in the analysis are summarized in Table 16.
 Table 16. Clinical characteristics
of the study participants 
(n=10 adult male 
subjects with T2DM, 
mean age 66.56 ± 
10.92). The data are 
presented as mean ± 
standard deviation.
Based on the qRT-PCR platform, the Exiquon miRCURY Serum/Plasma Focus microRNA 
PCR Panels I+II (V6.0) were used for miRNAs detection. 
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Each miRNA with cycle threshold (Ct) value less than 37 in the panel were included in 
data analysis. Furthermore, fold changes >2 or below -2 where considered for further 
investigations.
The internal spike-in (cel-miR-93-3p) to normalize samples, was not detected in one 
patient, thus it was excluded from clinical records. 
Totally, 77% of miRNAs in panels belonging to patients before starting soy supple-
mentation, and 81% of miRNAs in patients after treatment were detected. As given 
in Table17, 57 circulating miRNAs differed for about 2 fold between visit 1 and visit 2, 
including 7 up-regulated and 50 suppressed miRNAs. Among them miR-34a-5p, 
miR-144-3p and miR-19b-3p showed a P-value<0.05. Other three miRNA showed a 
statistically significant difference (miR-10b-5p, miR-193a-5p and miR-20b-5p), however 
their fold change is less than 2. 
Table 17. Differential expression of circulating miRNAs in T2DM and compensated hypogonadism subjects.
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6.  DISCUSSION
 In the last few decades the notion of diabetes has widened, ascertain that 
diabetes is a much more heterogeneous disease than the present subdivision into type 
1 and type 2 diabetes assumes. Both type 1 and type 2 diabetes seem to result from a 
collision between genes and environment. The change toward a more affluent Western 
lifestyle that has taken place during the last 50 years has started a worldwide epidemic 
increase in the prevalence of T2DM and obesity [7][130]. 
 All forms of diabetes are characterized by chronic hyperglycemia. Since the 
early 20th century, the diagnosis of diabetes has been based on the measurement 
of glucose concentrations in the blood [24]. In the past 25 years the measurement of 
HbA1c has been interpreted as routine useful integrated measure of glycemic control. 
However, several studies have highlighted the limits of its use in patients with underly-
ing disorders, including diseases changing erythrocytes turnover (hemolytic anemias, 
chronic malaria, major blood loss or blood transfusions), as well as genetic hereditary 
anemias and iron storage disorders that may influence the variability of HbA1c in 
populations [131]. Furthermore, it has been shown that HbA1c values may not be con-
stant among individuals despite the presence of similar blood glucose or fructosamine 
concentration [132].
 Monitoring of diabetic status is considered as a cornerstone of diabetes care. 
Over the past four decades, major advances have been done in the knowledge of the 
human genome, and the use of molecular biology tools has brought novel insights in 
the pathogenesis of human diseases and diabetes. However, mechanisms other than 
genetic ones are also involved in the pathophysiology of diabetes. This applies for the 
non-enzymatic post-translational modifications, which alter structural and biological 
properties of proteins and living organisms. 
 Non-enzymatic glycation has been strongly related to hyperglycemia conditions 
and therefore to chronic complications associated with diabetes. Protein glycation is a 
spontaneous reaction where reducing sugars interact with amino groups of proteins, 
which, as all spontaneous reactions, cannot be prevented [133]. The reaction is 
initiated by the formation of a Shiff base, which then undergoes an Amadori 
rearrangement to become a ketoamine, fructosamine when glucose is the reactive 
sugar [134]. Until recently, the formation of fructosamines was thought to be irrever-
sible, which unavoidably followed by their slow conversion into a series of compounds  
known as AGEs [64].
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These materials accumulate in tissue and plasma during aging and diabetes [40], and 
numerous studies have shown an association between AGEs and many age- and 
diabetes-related pathologies, including atherosclerosis, cataract, nephropathy, 
retinopathy, and Alzheimer’s disease [135].
Thus, the identification of an enzyme, FN3K, able to decompose fructosamine 
3-phospates to 3-deoxyglucoseone, inorganic phosphate and an amine [61] opened the 
perspective that fructosamines can physiologically be removed from proteins. For this 
reason, FN3K appear as a part of a protein repair system and/or cellular defense [136]
opposing to the consequences of hyperglycemia, controlling non-enzymatic glycation 
of proteins and therefore protecting from diabetic complications development. 
 Only Delpierre et al. proved a possible association between the variability of 
erythrocytes FN3K activity and genetic polymorphisms. This study, conducted on a 
Belgian cohort of T1DM patients, demonstrated the presence of 6 different 
polymorphisms: two in the promoter region and one in exon 6 of the gene, were 
significantly associated with the erythrocytes FN3K activity [71]. 
6.1 Genetic variations
 In this study, the FN3K gene was analyzed by direct sequencing in a population 
of Italian diabetic subjects. Then the presence of variants found in this first step of the 
work was verified in the control healthy group by using DHPLC, a less expensive and 
time consuming method that is successfully used for the analysis of already known 
genetic variants [125]. 
 Fifteen different genetic variants were identified: 4 in the promoter region; 7 
in coding regions (exons 1, 2, 4, 5, 6); while 4 located in non-coding portions (introns 2 
and 4); the detection of the latter was possible since also the intron/exon boundaries 
of FN3K gene were PCR amplified. Of these 15 variants, 5 were unpublished variants, 
2 were previously published by our group [76], while the remaining 8 were polymor-
phisms already reported in NCBI SNPs database. 
Among 7 new genetic variants, 4 were predicted as pathogenic: c.2 T>A; c.465 G>A; 
c.559 C>T and c.716 A>G using the Mutation Taster tool. The deleterious effects of 
these mutations on FN3K protein were confirmed using Polyphen2 [128] and SIFT [129] 
in silico softwares. 
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Variant c.2 T>A
 The variant c.2 T/A affected the start codon in exon 1, resulting in the elimina-
tion of the amino acid methionine at position 1 (p.M1?). The abolition of the transla-
tion starting site threatening protein production, that resulted in a complete absence 
of the FN3K enzyme encoded by the allele carrying the mutation. However, software 
analysis predicts the presence of another ATG downstream the N-terminal region. This 
new translation starting site is in the same Open Reading Frame of the original ATG. 
As result, the new protein produced from the new starting site will be identical to the 
former protein but will lack of 50 amino acid (p.Met1_Gln50del).
 The ATG triplette coding for first methionine, essential condition for protein 
translation, has to be located in a peculiar nucleotidic contest, namely Kozak sequence 
(gccRccATGG: nucleotide in capital letter are those majorly conserved; the R represent 
a purine). This sequence allowed the ribosome correct recruitment on the mRNA. The 
new ATG didn’t present a similar contest around, but the protein translation from this 
site cannot be excluded. The mutated protein will lack of 50 amino acids in the 
N-terminal region (16% less of the wild type protein). Nevertheless, the catalytic site of 
the enzyme is located in the C-terminal region, thus, this mutated enzyme could 
equally exert its function if translated. 
Variant c.465 G>A
 The variant c.465 G>A caused the substitution of the third nucleotide of CCG 
triplette, coding a proline at codon 155, with an A, leading to the formation of a CCA 
triplette encoding for the same amino acid (p.P155=). This synonymous mutation is 
located few nucleotides from the splicing site region. 
 The pathological effect of this variant lies in the fact that it could alters the 
splicing process potentially affecting the mRNA maturation. In details, the splicing site 
located 3 nucleotides downstream the alteration will be abolished, leading to intron re-
tention. An aberrant mRNA and a protein with an altered function would be produced 
or the mutated allele could not produce the protein.
Variant c.559 C>T and variant c.716 A>G
 The variant c.559 C>T caused the substitution of an arginine into a premature 
stop codon at codon 187 (p.R187*). This premature signal for termination of transla-
tion causes a resulting protein that is abnormally shortened, lacking of part of exon 5 
and all exon 6. Amino acid homologies studies between human FN3K and homologous 
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proteins from different organisms revealed that the most significant regions of amino 
acid identified are located in the carboxy termini of the proteins and that this region 
probably represents the ATP binding site [63]. In the case of human FN3K, this impor-
tant region corresponds to exon 6 that can be therefore considered fundamental for 
the proper function of the enzyme. For this reason, its absence caused by mutation 
p.R187* is probably connected with an altered enzymatic activity. In addition we 
cannot exclude that the truncated protein is degraded or not targeted to its final 
destination.
 Also the second mutation (c.716 A>G; p.Y239C) has got an important functional 
meaning. It is localized in a conserved region of exon 6 and involves the substitution at 
codon 239 of a tyrosine into a cysteine, an aminoacid containing sulfur implicated in 
the disulfur bonds formation which could allow the effects of structural changes within 
the protein and therefore an alteration of the normal enzymatic activity.
 Additional three new variants have been identified: two in the promoter region 
(c.-421 C>T and c.-429delATCGGAG) and one in intron 2 (IVS2-27 A>G). 
 The intronic variant IVS2-27 caused a substitution of an A with a T, 27 nucleo-
tides upstream exon 3. It was classified as a polymorphism by Mutation Taster. The 
software predicted an ineffective role of the variant in influencing the slicing since it 
isn’t located in a consensus sequence for splicing.
 Regarding the FN3K promoter region, it has been previously examined and de-
scribed [63]. FN3K core promoter region was identified 252 bp upstream the transcrip-
tion start site. Its sequence is consistent with those of housekeeping genes: it lacks of 
consensus TATA- and CAAT- boxes and it is rich in GC content, consistent with the 
hypothesis that FN3K gene could be co-ordinately regulated by CpG island-driven core 
promoters. Moreover, FN3K promoter contains two possible binding sites for NFκB 
transcription factor (-53 and -58 bpwith the respect of ATG) [63]. The 2 variants 
detected in the promoter region, c.-421 C>T and c.-429delATCGGAG, were found in 2 
subjects, with T1DM and T2DM, both in heterozygous state. The first one, caused the 
substitution of an A in a T at position -421 (c.-421 A>T); while the second one, 
consisted in a 7 nucleotides deletion (variant c. -429delATCGGAG). These variants are 
located very far from transcription factor sites and the fact that are present in more 
than one subject leading to the hypothesis that such variants are ineffective 
polymorphisms more than mutations.
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 The other genetic variants identified in our study were 8 polymorphisms 
already described and present in the NCBI SNPs database: 2 are located in the
promoter region (c.-232A>T and c.-385 A>G); 1 in exon 2 (c.187 A>C); 2 inintron 2 
(IVS2+26 G>A and IVS2+31 A>T); 1 in intron 4 (IVS4-9-11delTTG), consisting in a dele-
tion of three nucleotides very closed to the consensus sequence for splice sites, and 
2 in exon 6 (c.900 C>G and c.906 C>T). It is reported that more than 90 % of SNPs are 
in introns or in inter-genic regions, and most of them are probably of little functional 
consequence. However, SNPs in promoter regions can alter the affinity of DNA-binding 
proteins and modify the level of gene expression; other SNPs in exon/intron bounda-
ries result in intron retention or exon skipping, thus profoundly changing the structure 
of the resulting protein. It is also possible that the intron where the SNP is located can 
function as an RNA interference element [137].
 None of the polymorphisms identified in this study resulted in a modification 
of the sequence of the encoded protein or was present in a consensus sequence for a 
splicing site or in a site for transcription factor, but a possible modulatory role in gene 
regulation or expression or in differential splicing[138] cannot be excluded. This 
hypothesis is supported by Delpierre’s findings [71]: the differences in erythrocyte 
FN3K activity are due to sequence variations in or near the FN3K gene, which don’t 
cause any change in the sequence of the protein. To this respect, polymorphism 
c.900 C>G is of particular interest, since it is the only exon-encoded polymorphism 
found to be significantly associated with the erythrocyte FN3K enzymatic activity [71]; 
in particular, the presence of the non ancestral allele C seems to cause its increase.
An effective role of polymorphism c.900 C>G in diabetes has also been demonstrated in 
another work conducted by an Hungarian research group [73]. This polymorphism was 
analyzed in T2DM and in the case of the CC allelic combination, T2DM was diagnosed 
at a later age than in the case of CG or GG genotypes. Moreover, diabetic individuals 
with the CC genotype had lowerHbA1c levels compared with the others, although the 
N-terminal valine of the β-chains that forms HbA1c is reported as a poor substrate for 
FN3K [66]. Moreover, further evidences on an effective association of such 
polymorphism to diabetes came to light in recent years. Indeed, an association of 
c.900 C>G with the progression of diabetic nephropathy and cardiovascular morbidity 
and mortality was reported [74]. Recently, Škrha and co-workers, linked the GG 
genotype of polymorphism c.900 C>G to a decrease of sRAGE concentration. Therefore 
the genotype CC for the polymorphism c.900 C>G seems to have a protective role in 
T2DM. In our opinion, these findings are very useful for our research since they link the 
potential impact of FN3K on HbA1c levels and typical aspect of diabetes.
86
6.2 Association studies
 Hemoglobin A1C is formed by the non-enzymatic attachment of glucose to the 
N-terminal valine of the β-chain of hemoglobin [139]. HbA1C reflects long-term 
glycemic exposure, representing the average glucose concentration over the preceding 
8–12 weeks [121][140]. 
 The A1C assay is the “gold standard” for the diagnosis of diabetes. Its formation 
is directly proportional to the glucose concentration to which erythrocytes are exposed 
during circulation, since they are permeable to glucose [141]. The life span of 
erythrocytes is 120 days, however, glycation of protein with a much longer half life, 
could lead to their inactivation and aggregation thought AGEs formation. This 
mechanism has been hypothesized to be one of the causes of diabetic complications 
development. FN3K with its deglycating function would be able to remove glycation 
product from proteins suggesting a protective role in the development of such 
complications [66]. 
 However, variants in the FN3K gene could alter its enzymatic activity and con-
sequently the progression of diabetic complications. Three polymorphisms have been 
identified in this respect: two in the promoter region (rs3859206, rs2256339) and one 
in exon 6 (rs1056534). In details, genotypes GG at position -385, TT at position -232 
and CC at c.900 have been associated with a better performance of the FN3K
enzymatic activity [71]. Moreover, the latter has been also associated with lower HbA1c 
values [73].
 For this reason a genotype composed by the combination of these polymor-
phisms has been considered. Thirteen genotypes have been identified (Table 11) and 
HbA1c mean values for each genotype have been compared (Fig. 41). It has been ob-
served that subjects carrying the favorite alleles for the tree polymorphisms, indicated 
by genotype A, displayed HbA1c values lower than those with genotype C. However, 
this difference was not statistically significant (Cohort 1 p= 0.1416; Cohort 2 p=0.3779; 
Total p=0.1749). 
This genotype, even the small number of patients analyzed, seems to be associated 
with a lower concentration of HbA1c values in T2DM patients, consistent with the 
results of Mohàs et al. [73] regarding the rs1056534. The finding that these patients 
present also the GG genotype for rs3859206, associated with a better performance 
of the FN3K enzyme [71], add new useful information reinforcing the idea that these 
two variants could act together and influence the FN3K enzymatic activity, varying the 
amount of HbA1c. 
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 Moreover, it has been observed that some genotypes identified in subjects with 
macro-vascular complications were absent in patients with microvascular complica-
tions and vice versa. This observation could represent a new step in early diagnosis of 
diabetic complications. Identification of specific polymorphisms in an early stage of the 
disease or during the asymptomatic period could be useful especially in familial cases 
allowing a prompt intervention and promising a better prognosis.
 Finally, in cohort 2 a significant association of the C allele of polymorphism 
in exon 6 (c.900 C>G, rs1056534) with diabetic nephropathy was not observed 
(p=0.7305), maybe for the small number of patients presenting such complication. 
6.3 Mutation pathogenicity and familial study
 The FN3K gene analysis identified four likely pathogenic variants (c.2 T>A; 
c.465 G>A; c.559 C>T and c.716 A>G). These genetic variants were found in the hetero-
zygous state in only one subject in all cases with T2DM. All of them were not detected 
in any subjects of the control group. Moreover, these mutations were never described 
before and could represent a new step in the identification of genetic risk factors for 
T2DM.
 An RNA expression study was performed in order to confirm the hypothesis on 
pathogenicity of these mutations found at genomic level. However, this analysis didn’t 
confirm the result predicted in silico, suggesting that these variants could exert a 
pathological function with other mechanisms or interacting with other variants present 
in the FN3K gene. 
 Variants c.559 C>T (p.R187*) and c.716 A>G (p.Y239C) in the FN3K gene were 
analyzed also in the familial context. Furthermore, index cases relatives were tested for 
the presence of the three polymorphisms mostly associated with FN3K activity. 
 Family 1 (Fig. 51) harboured the missense mutation p.Y239C and consisted of 
four subjects: the index case and three siblings, one brother and two sisters. All family 
members presented T2DM, except for the younger sister that has T1DM. The analysis 
of the FN3K variants has demonstrated the presence of the c.716 A>G mutation in 2 
siblings: proband’s brother (II:1) and younger sister (II:2). The analysis of the other 
polymorphisms highlighted that all subjects carrying the mutation presented the same 
genotype forthe other polymorphisms under investigation (Table 12). 
 Regarding family 2 (Fig. 52) harbouring truncating mutation p.R187*, only the 
brother (II:1) of the index case underwent on genetic test. Proband’s brother at the 
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moment of the test didn’t present any symptoms of diabetes. The FN3K screening 
didn’t find out the presence of the mutation. Moreover, in this family the two siblings 
displayed the same genotype for the other polymorphisms under investigation. 
 These results are hard to evaluate since the role of FN3K variants in the deve-
lopment or progression of diabetes is not yet clear. The lack of an association between 
some polymorphisms identified in the FN3K gene and DM explains that probably this 
enzyme cannot by itself account for the entire deglycation story; it alone cannot be 
responsible for the susceptibility to this pathology or for the development of its com-
plications. However, a better knowledge of FN3K and its aspect could be considered 
useful since it may be associated with an increased risk on DM onset, reported as a 
multifactorial disease. 
6.4 MicroRNA
 Previous literature has demonstrated that endogenous serum and plasma miR-
NAs are sufficiently stable and quantifiable to serve as clinical biomarkers of diseases 
including diabetes[142][143][144]. Mitchell et al. [143] found that the abundance 
of miRNAs in serum and plasma were strongly correlated, which indicates that both 
serum and plasma samples would be suitable for investigations of miRNAs as blood-
based biomarkers.
 Mammalian circulating miRNAs are packaged inside lipid or lipid-protein com-
plexes, such as microvesicles, exosomes or apoptotic bodies [95][96], or in associations 
with proteins [100]. miRNAs secreted inside exosomes may have a different fate com-
pared with those associated with proteins or HDL[98]. Moreover, specific miRNAs tend 
to be preferentially released by cells and are thus more prone to be found in circulation 
[145]. Although emerging evidence has established that extracellular miRNAs 
contained in the body fluids have distinct physiological function [143][144], the main 
function and the meaning of the existence of circulating miRNAs remain elusive.
 The expression of circulating miRNA in plasma samples of patients with T2DM 
and compensated hypogonadism exposed to soy treatment for twelve weeks has been 
analyzed. The miRCURY LNA RT-qPCR system were chosen for this analysis because it 
has been found to be more sensitive and reproducible than microarray systems and 
showed even more sensitivity and linearity than TaqMan methods at low concentration 
of plasma miRNA [146].
 Three miRNAs, miR-34a-5p, miR-144-3p and miR-19b-3p, were found to be up-
regulated and showed a statistically significant difference between pre and post soy 
89
treatment. Among them, there are evidences on miR-144 to be up-regulated by 
estrogens in cancer cells and cancer-associated fibroblasts [147]. Furthermore, miR-144 
was also linked to T2DM. Its expression is up-regulated in T2DM and impairs insulin 
signaling through down-regulation of insulin receptor substrate 1 (IRS1) [148] in 
impaired fasting glucose and T2DM patients.
 Soy has shown to have beneficial effects on the management of cardiovascular 
disease and diabetes [149]. In this study, after soy supplementation changes in 
testosterone levels, in glycemic control and cardiovascular risk markers were observed. 
Moreover, the number of expressed miRNA seemed to increase after treatment. 
 A consistent and truly significant effect of soy on the miRNAs plasma profile 
could not be demonstrated since a validation study is needed to confirm these findings 
and to proceed with further evaluation. However, these preliminary results are encou-
raging for future investigation on soy isoflavones potential and for miRNA utilization as 
non-invasive biomarkers. 
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7.  CONCLUSIONS
 It is reported that the human genome of approximately three billion base pairs
(www.ornl.gov) contains at least 10 million SNPs. SNPs are defined as genetic variations 
present in the general population [150]. Human genetic variation occurs as a 
continuum, ranging from neutral polymorphisms, through functional polymorphisms 
and disease susceptibility variants to true pathogenic variantswith a high penetrance. 
 For decades, investigators have worked to unravel the role of genetics in type 2 
diabetes through epidemiological studies, studies of candidate genes, and genetic 
linkage in families. Over the past year, a number of articles have been published based 
on high-throughput genome-wide association studies (GWAS). These have not only 
uncovered a number of new genetic loci associated with diabetes and provided new 
targets for mechanistic investigation, but have also forcing us to reconsider the degree 
of genetic heterogeneity and possibly even the role of genetics itself in the pathoge-
nesis of diabetes.
 It has become increasingly clear that our genomes contain many ‘putatively 
disadvantageous variants’ that are probably insufficient on their own to cause disease, 
but nevertheless still have the potential to contribute to pathogenesis. Moreover, it has 
also become clear that many genetic disorders are not monogenic as originally 
supposed, but may instead involve mutations in two or more genes. It could be 
speculated that different combinations of pathological mutations with low penetrance, 
functional polymorphisms, disease susceptibility variants and ‘putatively disadvanta-
geous variants’ may vary quite considerably in terms of their net functional and hence 
clinical effect[151]. 
Diabetes management and/or prevention should aim to incorporate genetic and 
molecular screens to tailor specific treatments (therapeutics as well as lifestyle 
changes) and optimize benefits for patients. 
 FN3K appears to be part of a cellular defense and/or repair system to control 
non-enzymatic glycation of proteins. FN3K would be able to oppose one of the chemi-
cal consequences of hyperglycemia, exerting a protective function in the development 
of diabetic complications, which are reported to differ from individual to individual and 
to be at least partly genetically determined [152]. Therefore, it could be hypothesized 
that low activities of this enzyme will increase the glycation level of proteins, and in the 
case of some specific proteins, participate in the development of complications. This 
could happen through a direct as well as indirect action. Erythrocyte FN3K enzymatic
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activity was found associated with some polymorphisms in the FN3K gene. Therefore 
the identification of novel SNPs/mutations in this gene is of great interest. 
 Up to now, this study allowed the identification of 15 genetic variants in the 
FN3K gene. Seven were novel: 3 missense mutations, 1 synonymous mutation and 3 
polymorphisms (1 intronic and 2 in the promoter region). The remaining 8 variants 
were classified as polymorphisms. 
 The three SNPs detected by Delpierre et al. founded associated with the 
erythrocyte FN3K enzymatic activity [71], didn’t change FN3K aminoacidic sequence. 
For this reason, focusing the attention not only on mutation causing an aminoacid 
change, but also on silent alterations or polymorphisms present in non-coding regions 
is necessary. Moreover, it has been reported that many causal variants responsible for 
some common complex disorders are really non-coding[138]: such variants probably 
don’t influence directly the protein function, but produce a quantitative effect on pro-
tein expression acting on mRNA stability or on trascriptional capacity of the gene. This 
study add new useful informations to works concerning the molecular characterization 
of FN3K gene.
 A limit of this work is the lack of the measurement of FN3K enzymatic activity; 
knowing the correlation between FN3K genotype and enzymatic activity in different 
diabetic patients, divided according to stage and type of complication, may help to 
understand the real role of this enzyme and its possible involvement in the pathology. 
If such involvement really exists, the gene encoding FN3K would be added to the list of 
all other genes found associated with diabetes through the GWA studies performed till 
now.
 By demonstrating the association between a gene and a disease, the studies 
uncovered new etiological pathways to be explored, leading to improve prevention and 
specific treatments for patients. Increasing expression of enzyme against glycation is 
thought to provide a novel and potentially effective future therapeutic strategy to 
suppress protein glycation [54].
 The lack of association between some polymorphisms identified in FN3K gene 
and DM suggests that probably the role of FN3K in glycation of biological proteins 
seems to be more complex than evident at a first glimpse. The variability of FN3K 
activity may provide another key of explanation in those circumstances in whom HbA1c 
does not perfectly correlate with the mean glucose level [153]. It has been shown that 
HbA1c values may not be constant among individuals, despite the presence of similar 
blood glucose or fructosamine concentration [154]. It would be interesting to expand 
these studies and to correlate the FN3K activity with the glycation gap and with the
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development of diabetic complications. Indeed, probably also other molecular mecha-
nisms impacting gene expression and activity of enzymes in deglycation process may 
have to be taken into account [132]. 
 Larger studies are necessary for a better understanding of the possible effect of 
FN3K genetic variants on the progression of the disease and its possible clinical util-
ity in the management of diabetic patients. One of the future aims is to genotype the 
FN3K gene in other diabetic and control subjects in order to expand the studied co-
horts and to make statistical analyses more significant. 
 Other future perspective is the development of a method for measuring FN3K 
enzymatic activity in order to find a possible correlation between this parameter and 
each SNPs/mutation identified in the genetic analysis. 
Indeed FN3K represents a piece in the puzzle of diabetes disease.
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